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ABSTRACT OF THE DISSERTATION 
 
NRF2-Independent Regulation of Drug Metabolism by CAR and Prooxidants. 
 
by 
 
Miles Paszek 
Doctor of Philosophy in Chemistry 
University of California San Diego, 2020 
 
Professor Robert Tukey, Chair 
Professor Neal Devaraj, Co-Chair 
 
 Exposure to toxicants that create oxidative stress, such as isothiocyanates 
(ITCs) and heavy metals, initiate inductions of antioxidant response genes and 
detoxification genes such as glutathione S-transferases (GSTs) and UDP-
glucuronosyltransferases (UGTs) by the NRF2-KEAP1 pathway. UGTs act on a wide 
range of hydrophobic compounds, including the heme-degradation product, bilirubin, 
xv 
 
which can only be conjugated by UGT1A1. Newborn humans commonly exhibit an 
accumulation of bilirubin in the serum known as hyperbilirubinemia due to a 
developmental delay in the transcription of UGT1A1. This effect is replicated in 
neonatal mice that lack a functional mouse Ugt1 locus but contain the human UGT1 
locus. These hUGT1 mice experience neonatal hyperbilirubinemia that can be 
ameliorated by the induction of UGT1A1 by active nuclear/xenobiotic receptors. The 
crossing of hUGT1 mice with nuclear/xenobiotic receptor knockout mice creates a 
mouse model that links a readily observed phenotype, hyperbilirubinemia, with 
nuclear/xenobiotic receptor function following exposure to a desired compound. 
Phenylethyl isothiocyanate (PEITC) treated neonates experienced a reduction of total 
serum bilirubin levels, and an induction of hepatic and intestinal UGT1A1 and the 
CAR target gene, CYP2B10. Utilizing hUGT1/Car-/-, it was determined that PEITC 
induced hepatic UGT1A1 in a CAR-dependent manner. It was also shown that some 
CAR-independent induction of intestinal UGT1A1 occurred.  Inductions of CYP2B10 
and UGT1A1 could be blocked by pretreatment with the antioxidant, N-acetyl 
cysteine (NAC), which indicates oxidative stress as a component to CAR activation. 
To examine the role of NRF2 on intestinal induction of UGT1A1 by PEITC, 
hUGT1/Nrf2-/- mice were generated. Intestinal UGT1A1 induction by PEITC was 
determined to be partially dependent upon NRF2, while Cyp2b10 and hepatic 
UGT1A1 induction was retained in hUGT1/Nrf2-/- mice. This indicated that CAR 
activity following PEITC exposure does not require NRF2. Similar results were 
obtained with the heavy metals arsenic and cadmium in the small intestine. Western 
blot analysis of intestinal fractions of hUGT1/Nrf2-/- mice treated with CdCl2 
xvi 
 
demonstrated increases in nuclear CAR accumulation, nuclear P38 content, and the 
rise and fall of ERK1/2 phosphorylation. Mitogen activated protein kinase activity may 
serve as the regulatory mechanism for CAR activation by oxidative stress. 
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CHAPTER 1: INTRODUCTION 
Section: 1.1 Oxidative Stress  
Under some conditions oxidative modifications to proteins, lipids, and small 
molecules serve necessary signaling functions1. However, excessive modifications of 
proteins, lipids, and nucleic acids affect electrostatic interactions resulting in altered 
structures and in some cases a loss of function. Excessive loss of function puts the 
cell in a state of distress, which is known as oxidative stress. The redox state of any 
compartment within the cell is variable and is regulated by enzymatic and non-
enzymatic redox reactions that alter the flux of reactive oxygen, nitrogen, carbon, and 
sulfur species. 
Typically, the major contributors to the redox state of a cell are 
enzymatic/protein-related processes. For example, mitochondria are the principal 
source of reactive oxygen species (ROS), which are generated by NADPH oxidases, 
dehydrogenases, and respiratory complexes I-III 2,3. Most enzymatic methods reduce 
oxidative damage by either directly targeting ROS or the secondary oxidized products 
formed by ROS, such as lipid peroxides and glutathione disulfide (GSSG). Some of 
the most notable enzymes include superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (GPX), and glutathione-disulfide reductase (GSR).  
Glutathione (GSH) is one of the most important intracellular antioxidants, and 
the ratio of reduced glutathione to oxidized glutathione is used as a loose measure of 
the oxidative state of a cell. The variability of glutathione concentrations and ratios 
are dependent upon the cell type and compartment, making certain organelles, cells, 
and tissues are more susceptible to oxidative damage. Those cells that experience 
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high rates of ROS generation or those compartments that have low levels of GSH 
available for an antioxidant response are more susceptible to oxidative stress. 
Indirectly, stress can be generated by depletion of cellular antioxidants and by less 
reactive small molecules that dysregulate the antioxidant response; therefore, these 
compounds must be detected and removed.   
Experimentally, oxidative stress can be detected through RT-PCR of gene 
transcripts encoding antioxidant response proteins, spectrophotometric measurement 
of glutathione conjugates, and through immunohistochemical targeting of residues 
modified by reactive species.  
Section: 1.2 Drug Metabolism  
Drug metabolism (which herein refers to both xeno- and endobiotic 
metabolism) is described by 4 phases: absorption/uptake (phase 0), 
oxidation/reduction and hydrolysis (phase I), conjugation (phase II), and transport 
and excretion (phase III). Drug absorption is dependent upon several properties, 
such as route of exposure, hydrophobicity, and mechanism of uptake (e.g., passive 
diffusion, active transporters, etc.).  
The major routes of exposure for most xenobiotics are inhalation via the lungs 
and orally via the gastrointestinal tract due to the relatively large surface areas that 
are essential for satisfactory gas exchange and nutrient uptake, respectively. Certain 
xenobiotics are absorbed only after their formation from pro-forms by the microbiota. 
An example are isothiocyanates (ITCs), such as sulforaphane and phenylethyl 
isothiocyanate, which exist as glucosinolates glucoraphanin and gluconasturtiin, 
respectively. These pungent compounds are natural pesticides found in cruciferous 
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vegetables that undergo cleavage by myrosinase upon damage to the plant by 
mastication, or by gut microbiota4. These small hydrophobic ITCs are readily and 
rapidly absorbed giving them a high bioavailability5. 
In contrast to the unassisted diffusion that enables small hydrophobic 
compounds to be absorbed, certain toxicants like heavy metals As3+ and Cd2+ are 
primarily taken up by facilitated diffusion or active transport processes, which can 
limit their accumulation depending on protein levels and competition. For example, 
cadmium uptake is dependent upon DMT16 and ZIP87, which limits GI absorption to 
~3%8. These transporters are also utilized for iron and zinc uptake, and competition 
with these transporters and other ion gates can disrupt regulatory processes6. 
Certain conditions, like anemia, facilitate Cd2+ uptake due to increased transporter 
expression, which can increase absorption up to 15-20%9. The complexity of toxicant 
absorption can be further increased if multiple routes of exposure are considered. For 
example, Cd2+ can also be taken up by the lungs from cigarette smoke, and the 
absorption is ~25% via inhalation10. Multiple exposure routes increase an individual’s 
risks and impact which organs will experience toxic effects, particularly when those 
organs are poorly suited to perform phases I, II, and III of drug metabolism. 
During phase I of drug metabolism, small molecules are typically oxidized by 
class of monooxygenases known as cytochrome P450s (CYP450s). Other reactions 
such as reductions and cleavages occur, but the most prominent phase I modification 
is oxidation. The oxidation of small hydrophobic molecules serves to increase the 
molecule’s solubility, provide a functional group for further modifications, and 
sometimes inactivate the molecule. However, it should be noted that CYP450 action 
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can sometimes bioactivate molecules leading to an increase in their action, and in 
some cases, their toxicity. These CYP450s are localized to the cytoplasmic face of 
the endoplasmic reticulum and certain CYP450s, such as CYP3A4, have a dramatic 
range of pharmaceutical substrates. Competition for CYP450s and changes in their 
expression are major contributors to drug-drug interactions and the variability of drug 
efficacy and safety.  
In phase II of drug metabolism, small hydrophobic molecules are made more 
water soluble by conjugation reactions. There are multiple reactions that solubilize or 
inactivate compounds, such as glucuronidation, sulfation, and glutathione 
conjugation among others. Glucuronidation represents a significant source of 
xenobiotic metabolism that requires consideration when evaluating drug therapeutics. 
Glucuronidation is performed by UDP-glucuronosyltransferases (UGTs), which are 
localized to the endoplasmic reticulum and utilize uridine diphosphate glucuronic acid 
as a substrate for the conjugation of small lipophilic compounds. There are 19 
characterized in humans which are split into the UGT1, family containing 9 
transferases, and the UGT2 family, containing 10 transferases11. A variety of 
endogenous and exogenous compounds are metabolized by UGTs including the 
heme metabolite, bilirubin. 
In addition to the antioxidant function previously introduced, glutathione also 
serves as a nucleophile for a variety of addition and substitution reactions that occur 
both enzymatically and non-enzymatically. The conjugation by glutathione serves to 
both inactivate electrophilic and reactive centers such as epoxides or metals while 
increasing solubility of the substrate. The enzymatic catalyzed conjugation reactions 
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of glutathione are performed by glutathione S-transferases (GSTs) which can be 
found in the cytosol, the endoplasmic reticulum, and the mitochondria.  
Phase III of drug metabolism consists of transport of metabolites out of the 
liver or kidneys to be excreted from the body in the bile or urine. There are two 
superfamilies of drug transporters (also known as efflux pumps); they are the ATP-
binding cassette (ABC) transporters and the solute carrier (SLC) transporters and are 
driven by ATP hydrolysis and electrochemical gradients, respectively. Examples of 
these include the multidrug resistance-associated proteins (MRPs) and glucose 
transporters (GLUTs). Many efflux pumps, such as P-glycoprotein (P-gp/MDR1), are 
capable of binding to variety of substrates. The regulation and coordination of the 
different phases of drug metabolism is mediated by multiple sensors known as 
nuclear (NR) and xenobiotic receptors (XR).  
Nuclear and xenobiotic receptors are generally composed of a few domains, 
they contain a ligand independent activating function (AF1), a DNA binding domain 
(DBD), a short linker that enables regulation and conformation changes, a second 
activating function (AF2), and the ligand binding domain (LBD). Nuclear and 
xenobiotic receptors are capable of promiscuous binding to both endo- and 
xenobiotics, which induce conformational changes that enable specific protein-
protein interactions and subsequent post-translational modifications. These signals 
both regulate the trafficking of the receptor and its transactivation activity through 
transcription factor and enhancer site recognition. Two nuclear/xenobiotic receptors 
that have been well characterized include CAR and NRF2. 
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Section: 1.3 CAR  
The constitutive androstane receptor (CAR) also known as the constitutively 
active receptor was observed in HepG2 cells as a nuclear receptor that has high, 
basal levels of transcriptional activity and spontaneously localizes to the nucleus12. 
CAR’s activity is inhibited by cytoplasmic localization and can be activated by a direct 
ligand binding (direct activation) and or by signaling cascades (indirect activation). 
The ligand binding pocket of CAR prefers small hydrophobic compounds13 with some 
species-dependent ligand specificity; for example, mouse CAR (mCAR) is activated 
by TCPOBOP and human CAR (hCAR) is activated by CITCO14. Both the direct and 
indirect mechanisms make use of a single post translation modification to control 
CAR localization, which is the phosphorylation of the conserved threonine residue 
(38 in humans and 48 in mice)15. 
Threonine 38 is between the two zinc finger motifs of the DBD, which are 
destabilized when Thr38 is phosphorylated15. This phosphorylation is sufficient to 
completely inhibit CAR DNA binding and prevent nuclear localization15. The 
importance of this residue to CAR has been studied extensively with phosphomimetic 
mutants (Thr38Asp) and “dephosphorylated” mutants (Thr38Ala). Until recently, the 
kinase responsible for the phosphorylation of Thr38 was unknown but was eventually 
determined to be the P38 mitogen-activated protein kinase (MAPK)16, which we 
propose is a critical component in the mechanism by which oxidative stress affects 
drug metabolism. Through in vitro work involving the ectopic expression of CAR and 
P38, the use of chemical activators, and phosphomimetic mutants, a Co-IP study 
demonstrated that P38, and more effectively p-P38, can physically interact with CAR 
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to increase its transcriptional activity and phosphorylate Thr38-CAR to induce 
cytoplasmic localization17.  
The dephosphorylation of p-Thr38-CAR is performed by protein phosphatase 
2A18, which is composed of the scaffolding subunit A and the catalytic subunit C, and 
it currently unknown if a substrate adaptor, subunit B, is required for the 
dephosphorylation of CAR. It is known that the receptor for activated C kinase 1 
(RACK1) is required for PP2A to dephosphorylate p-Thr38-CAR18. The regulation of 
PP2A interaction with CAR is regulated in two parts: the first is through Tyr52-RACK1 
phosphorylation and the second is through accessibility to the PP2A:RACK1 binding 
interface of CAR19. The first method represents the canonical pathway by which CAR 
is indirectly activated by the suppression of receptor tyrosine kinases (RTKs) such as 
EGFR20, HGFR21, and IGF1R22. Activation of RTKs leads to increases in 
phosphorylation of extracellular signal-regulated kinases (ERK1/2) and 
phosphorylation of Tyr52-RACK1, which prevents RACK1 from interacting with CAR 
and prevents PP2A from dephosphorylating p-Thr38-CAR18. RACK1 is 
phosphorylated by c-SRC, which is a proto-oncogene tyrosine-protein kinase Src18, 
and it should not be confused with steroid receptor coactivator 1 (SRC1), which 
increases CAR activity in the nucleus23. c-SRC is activated in response to EGFR 
activation, and the inhibition of EGFR by phenobarbital is the classical indirect 
mechanism of CAR activation18.  
Following the phosphorylation of Thr38, CAR is sequestered in the cytoplasm 
as a homodimer in a complex with the cytoplasmic CAR retention protein 
(CCRP/DNAJC7/HSP40), heat shock proteins 70 or 90 (HSP70 and HSP90), and 
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phosphorylated ERK1/224,25. Not much is known about the exchange of one heat 
shock protein for another in the context of CAR regulation; however, increases in 
heat stress cause an accumulation of HSP70, which reduces the proteasomal 
degradation of CCRP, which subsequently accumulates and sequesters CAR in the 
cytoplasm24. Additionally, HSP70 directly interacts with CAR; however when CAR is 
directly activated by a ligand, an increase in CCRP ubiquitination occurs along with 
CAR translocation24.  
The role of ERK1/2 phosphorylation in CAR repression has been 
characterized as well. Phosphorylated ERK1/2 are only capable of binding p-Thr38-
CAR at the xenobiotic response site (XRS) near the C-terminus of the LBD26. The 
binding of ERK1/2 causes CAR to form a homodimer, which buries the interface for 
the binding of RACK1:PP2A, thereby preventing p-Thr38 from being 
dephosphorylated. The MEK1/2 inhibitor, U0126, is sufficient to both reduce the 
phosphorylation of ERK1/2, as expected, and increase nuclear localization of CAR21. 
It should be noted that only the basal transcriptional activity of CAR is increased 
without augmenting ligand induction. Less is known about how direct ligand binding 
causes CAR activation and what proteins are essential for the translocation 
processes. An overview of the regulation of CAR can be found in Figure 1.  
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Figure 1. Regulation of the constitutive androstane receptor (CAR). CAR is 
regulated by direct ligand binding and indirect phosphorylation cascades. CITCO and 
TCPOBOP are human and mouse CAR direct activators and phenobarbital (PB) is an 
indirect activator that inhibits EGF binding to activate CAR. Both mechanisms require 
PP2A activity. PP2A binding is inhibited by CAR homodimerization, which is 
controlled by pERK1/2, while unphosphorylated RACK1 mediates the PP2A-CAR 
interaction. Following dephosphorylation of p-Thr38-CAR, CAR translocates to the 
nucleus where it dimerizes with RXR at the phenobarbital responsive enhancer 
module (PBREM) to activate transcription of target genes such as Cyp2b10 and 
UGT1A1. Following transcription, p-P38 phosphorylates CAR initiating cytoplasmic 
translocation. Blue lines are CAR activating processes while red lines are CAR 
repressive processes.  
 
Section: 1.4 NRF2 
The Nuclear factor erythroid 2 like 2 (NRF2/NFE2L2) is a transcription factor 
that is sensitive to the redox state of the cell and regulates genes that mediate the 
antioxidant response. NRF2 is constitutively expressed and is regulated at the post-
translation level by the kelch-like ECH associated protein 1 (KEAP1), which targets 
NRF2 for proteasomal degradation27. The interaction between NRF2 and KEAP1 is 
mediated by the Neh2 domain of NRF2, which contains high (ETGE) and low affinity 
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(DLG) motifs that bind two separate molecules of KEAP128. Under basal conditions, 
KEAP1 orients the E3 ubiquitin ligase, CUL3, to enable proteasomal degradation of 
NRF2. Upon electrophilic modifications of KEAP1 cysteine residues, conformational 
changes occur that prevent ubiquitination of NRF2, however the precise changes that 
are responsible for the decrease in ubiquitination have not been completely 
characterized. Without degradation, NRF2 prevents KEAP1 from binding and 
degrading other NRF2 molecules, causing an accumulation of NRF2 and 
subsequently an increase in NRF2 activity29. Other mechanisms exist where NRF2 is 
activated by sequestration of KEAP1 by P6230. NRF2 and small Maf proteins (sMaf) 
bind to the antioxidant response element (ARE) to induce transcription of a variety of 
genes. These genes include the antioxidant proteins previously mentioned (section 
1.1), as well as heme oxygenase 1 (HO-1), NAD(P)H quinone oxidoreductase 1 
(NQO1), GSTs, MRPs, and UGTs31.  
 
Section: 1.5 The Humanized UGT1 Mouse Model  
Bilirubin is a metabolite of heme, and its accumulation in tissues gives them a 
yellow color, which is a sign of liver dysfunction known as jaundice. During neonatal 
human development, increased red blood cell turnover causes the accumulation of 
bilirubin in the blood and other tissues. The liver glucuronidates bilirubin via UGT1A1; 
however, there is a developmental delay in the transcriptional regulation of UGT1A1, 
which enables the accumulation of unconjugated bilirubin. This is because there are 
no other enzymes that can conjugate bilirubin to increase its hydrophilicity to enable 
elimination via bile.  Excessive accumulation of bilirubin in the serum is known as 
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hyperbilirubinemia and bilirubin accumulation in the brain causes damage known as 
kernicterus32. While kernicterus can be lethal, mild forms of hyperbilirubinemia, such 
as Gilbert’s syndrome, have been associated with positive effects such as reduced 
rates of cardiovascular disease33 these effects are putatively due to bilirubin’s 
antioxidant capabilities34. One of the tools created that could aid the study of these 
correlations is the humanized UGT1 mouse model. 
The generation of the humanized UGT1 mouse model began with transgenic 
incorporation of the human UGT1 locus (Fig. 2)35. A separate model was created in 
which a null mutation for mouse Ugt1 was generated by insertion of a neomycin 
resistance gene (neo) in place of the shared exon 436.  
 
Figure 2. The human UGT1 gene locus. The human UGT1 locus is comprised of 9 
functional isoforms that are differentiated by their first exon (green) and share the last 
4 exons (blue). The shared exon structure is also present in mice, enabling a 
complete mouse Ugt1-null model to be generated by insertion of a Neo gene marker 
in the shared exon 4.   
 
Crossing of Ugt1+/- mice resulted in the death of the majority of Ugt1-/- 
neonates by day seven. These deaths resulted from high levels of bilirubin causing 
kernicterus. However, by breeding the Tg-UGT1 mice with Ugt1+/- mice, it was 
determined that neonatal Ugt1-/- mice could be rescued by the human UGT1 gene 
locus37. Mice bearing the Tg-UGT1 in an Ugt1-null background will be referred to as 
hUGT1 mice.  
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The UGT1 gene locus is regulated by many NRs and XRs37 and changes in 
UGT1 transcript levels are assumed to result from changes in NR and XR activity 
when neonatal mice are treated with some compound as compared to controls. 
Changes in UGT1A1 expression can be observed in multiple ways, like the transcript 
and protein levels via RT-qPCR and Western blot analysis, respectively. 
Furthermore, those observations extend to metabolite concentrations, meaning TSB 
levels of mice can be leveraged as a phenotype indicative of NR and XR activity. The 
accumulation of bilirubin in serum, which is a spectroscopically observable phenotype 
is a direct measure of the global UGT1A1 enzyme activity; low UGT1A1 activity is 
correlated with high TSB levels. When a xenobiotic activates a NR or XR resulting in 
an increase in transcription of the UGT1A1 promotor, TSB levels drop. These 
assumptions and observations hold true in neonatal mice with hyperbilirubinemia that 
were acutely exposed to certain xenobiotics38.  
By crossing hUGT1 mice with those containing NR or XR-null alleles, an in 
vivo model was created that enabled examination of the contribution of the individual 
NR or XR in the regulation of UGT1 genes following xenobiotic exposure. In order to 
determine which model needs to be utilized, target genes associated with specific NR 
and XRs were examined for changes in expression. These targets genes are 
regulated by promotors containing binding elements specific to a given NR or XR. For 
example, Cyp2b10 is regulated by CAR while NQO1 is regulated by NRF2. By 
examining loss of induction of target genes and TSB levels, assertions can be made 
about the relative role of NRs or XRs in responding to toxicants. Utilizing 
hUGT1/CARKO and hUGT1/NRF2KO mice the induction of drug metabolizing 
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enzymes by prooxidant toxicants was investigated and found to activate the 
constitutive androstane receptor in an NRF2-independent fashion. This establishes a 
new role for CAR and a new mechanism through which toxicants and oxidative stress 
can affect drug metabolism. This work may provide a new model for examining the 
effects of environmental exposure to toxicants on an individual’s health and response 
to pharmaceutical therapies.   
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CHAPTER 2: THE ACTIVATION OF CAR BY OXIDATIVE STRESS 
Taken from: Yoda E, Paszek M, Konopnicki C, Fujiwara R, Chen S, and Tukey 
RH (2017). Isothiocyanates induce UGT1A1 in humanized UGT1 mice in a CAR 
dependent fashion that is highly dependent upon oxidative stress. Scientific Reports 
Vol 7. 
ABSTRACT  
Isothiocyanates, such as phenethyl isothiocyanate (PEITC), are formed 
following the consumption of cruciferous vegetables and generates reactive oxygen 
species (ROS) that leads to the induction of cytoprotective genes such as the UDP-
glucuronosyltransferases (UGTs). The induction of ROS activates the Nrf2-Keap 1 
pathway leading to the induction of genes through antioxidant response elements 
(AREs). UGT1A1, the sole enzyme responsible for the metabolism of bilirubin, can be 
induced following activation of Nrf2. When neonatal humanized UGT1 (hUGT1) mice, 
which exhibit severe levels of total serum bilirubin (TSB) because of a developmental 
delay in expression of the UGT1A1 gene, were treated with PEITC, TSB levels were 
reduced. Liver and intestinal UGT1A1 were induced, along with murine CYP2B10, a 
consensus CAR target gene. In both neonatal and adult hUGT1/Car-/- mice, PEITC 
was unable to induce CYP2B10. A similar result was observed following analysis of 
UGT1A1 expression in liver. However, TSB levels were still reduced in hUGT1/Car-/- 
neonatal mice because of ROS induction of intestinal UGT1A1. When oxidative 
stress was blocked by exposing mice to N-acetylcysteine, induction of liver UGT1A1 
and CYP2B10 by PEITC was prevented. Thus, new findings in this report link an 
important role in CAR activation that is dependent upon oxidative stress.  
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INTRODUCTION  
The consumption of cruciferous vegetables such as broccoli, watercress, and 
cauliflower have been correlated through epidemiological studies with a lower 
incidence of cancer development39–41. These vegetables are abundant in 
glucosinolates, which are hydrolyzed by plant myrosinase and by microflora of the 
gastrointestinal tract to form isothiocyanates (ITCs), commonly regarded as 
conveying active anticarcinogenic activity42,43. The anticarcinogenic activity of ITCs 
has been linked to the activation of the nuclear factor erythroid 2 related factor 2 
(Nrf2)-Keap1 signaling pathway44, which is followed by binding of the transcriptional 
factor Nrf2 to antioxidant response elements (AREs)45,46. Prominent in this induction 
process are the cluster of genes that encode proteins involved in limiting both 
endogenous and exogenous chemicals from initiating deleterious biological effects by 
directing their metabolism, an event that biologically inactivates the agents and in 
many cases, facilitates their excretion from the body. This cumulative defense 
system, carried out by proteins that have been classified to participate in Phase II 
drug metabolism, prevents chemical induced toxic/genetic mutations and limits 
induction of epigenetic events that might lead to cellular proliferation and tumor 
development47.  
The UDP-glucuronosyltransferase (UGT) family of proteins are part of the 
Phase II cluster and participate in the detoxification and genoprotective process by 
converting target substrates to water soluble products by glucuronidation48,49. Once 
the glucuronides are formed, the soluble metabolites are transported out the cell, in 
many instances through high affinity transporters50–52, and become sequestered in 
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the water compartments of the tissue that eventually lead to elimination. Thus, the 
UGTs play a key role in detoxification of many endogenous agents, such as steroids 
and bile acid, hundreds of therapeutically consumed drugs, and environmental 
toxicants that are known mutagens and carcinogens49. The substrate specificity 
attributed to UGTs occurs in part because of a large and diversified gene family of 
proteins. In human, 19 UGTs have been identified, with each being classified into the 
UGT1 (UGT1A1, -1A3, -1A4, -1A5, -1A6, -1A7, -1A8, -1A9 and -1A10) or UGT2 
family (-A1, A2, -A3, -B4, -B7, -B10, -B11, -B15, -B17 and -B28)53. Each of the UGT 
genes is dynamically regulated, as evident from unique expression patterns observed 
in human tissues49. When human tissues were examined to document gene 
expression patterns, each tissue displayed a unique complement of the UGTs, 
providing evidence that tight tissue specific regulation leads to diversified 
glucuronidation activity54–57.  
Cellular and molecular events that underlie the regulation of the UGTs, 
especially those encoded by the human UGT1 gene family, have been studied in 
humanized transgenic mice that express the human UGT1 locus in a Ugt1-null 
background (humanized UGT1 mice)58. Developmental and tissue specific regulation 
of UGT1A genes has been shown to reflect similar patterns of expression as 
characterized in human tissues35. For example, the human UGT1A1 gene, which is 
developmentally delayed in newborns59, is also developmentally repressed in hUGT1 
neonatal mice60. Since UGT1A1 is the sole enzyme responsible for the metabolism of 
serum bilirubin61, this delay in UGT1A1 expression leads to severe neonatal 
hyperbilirubinemia in hUGT1 mice. The UGT1A1 gene can be transcriptionally 
17 
 
induced by a host of xenobiotic nuclear receptors, including the pregnane X receptor 
(PXR)62, the constitutive androstane receptor (CAR)63, the peroxisome proliferator-
activated receptor alpha (PPARα)38, the liver X receptor (LXR), and the 
environmental sensors, Ah receptor64,65 and Nrf266. The oral or intraperitoneal 
administration of ligands capable of activating these receptors in neonatal hUGT1 
mice leads to the induction of liver or intestinal UGT1A1 followed by dramatic 
reductions in total serum bilirubin (TSB) levels. Induction of UGT1A1 following 
activation of the Nrf2-Keap1 signaling pathway by oxidants, such as tert-
butylhydroquinone, implicates a potential role for the AREs responding to oxidative 
stress in control of the UGT1A1 gene66.   
It is generally believed that ITCs, such as phenethyl isothiocyanate (PEITC), 
induce UGT1A1 through activation of the Nrf2-Keap1 pathway, since the UGT1A1 
gene is a known target of Nrf266. We have extended these findings by treating 
neonatal and adult hUGT1 mice with PEITC and have evaluated the impact of ITCs 
in vivo for its capability to reduce serum bilirubin in neonatal mice while inducing a 
genome wide array of potential target genes. We will demonstrate that along with 
Nrf2 response genes, such as Nqo1 being significantly induced in adult hepatic 
tissue, CAR dependent target genes, such as Cyp2b10, are also upregulated. In 
addition, evidence will be presented linking the generation of reactive oxygen species 
(ROS) by PEITC in neonatal intestinal tissue to activation of intestinal epithelial cell 
maturation, a process that was recently shown to be linked to derepression of the 
nuclear corepressor protein NCoR1 and induction of intestinal UGT1A167. These 
observations led us to examine in greater detail the potential cross-talk between the 
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PEITC generated antioxidant response and CAR activation, and the implications of 
reactive oxygen species (ROS) on activation and induction of UGT1A1.  
    
MATERIALS AND METHODS  
Chemical reagents  
Phenethyl isothiocyanate (PEITC) and N-acetyl-L-cysteine (NAC) were 
obtained from SigmaAldrich (St. Louis, MO). Rabbit anti-UGT1A1 monoclonal 
antibody was purchased from abcam (Cambridge, UK). Mouse anti-GAPDH 
monoclonal antibody and rabbit anti-CYP2B9/10 antibody were obtained from Santa 
Cruz Biotechnology (Dallas, TX). Anti-p-p38, anti-p38, anti-mouse IgG horseradish 
peroxidase (HRP) conjugated antibody and anti-rabbit IgG HRP conjugated 
antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA).  
Animals  
Transgenic mice expressing the human UGT1 locus (UGT1A1*1) in a Ugt1-/- 
background (hUGT1)68 were developed previously58. hUGT1/Car-/- mice were 
constructed previously60. All animals were housed at the University of California San 
Diego (UCSD) Animal Care Facility and received food and water ad libitum. All 
animal use protocols, mouse handling, and experimental procedures were approved 
by the UCSD Animal Care and Use Committee (IACUC), and these protocols were 
conducted in accordance with federal regulations.  
For neonatal studies, 10-day-old hUGT1, hUGT1/Car+/- or hUGT1/Car-/- mice 
were treated by oral gavage with corn oil (vehicle) or 50 to 200 mg/kg PEITC 
dissolved in vehicle. Blood and tissues were collected as indicated in the figures. For 
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adult studies, vehicle or PEITC (200 mg/kg) was orally administrated to 6-week-old 
male mice every day for 4 days and tissues were collected 5 days after PEITC 
administration.  
Administration of PEITC, arsenic and antioxidant NAC  
Adult hUGT1 male mice (3 weeks old) were divided into 4 groups (n = 3-4 per 
group): control + vehicle group was given drinking water for 3 weeks and then 
administrated vehicle (corn oil) orally for 4 days; control + PEITC group was given 
drinking water for 3 weeks and then PEITC (200 mg/kg) was administrated orally for 
4 days; N-acetyl cysteine (NAC) + vehicle group was given 40 mM NAC in drinking 
water for 3 weeks and then vehicle (corn oil) was administrated orally for 4 days; 
NAC + PEITC group was given 40 mM NAC in drinking water for 3 weeks and PEITC 
(200 mg/kg) was administrated once a day for 4 days by oral gavage. Tissues were 
isolated five days after vehicle or PEITC administration.  
Neonatal hUGT1 mice (10 days old) were given an oral dose of NAC (75 
mg/kg) 1 hour prior to the oral administration of arsenic (As3+) at a dose of 10 mg/kg. 
Forty-eight hours later TSB levels were taken and tissue was collected. For PEITC 
treatment, neonatal mice were given an oral dose of 200 mg/kg and TSB levels 
measured after 48 hours and tissues collected.  
Bilirubin measurements  
A few drops of blood were obtained from the submandibular vein and 
centrifuged at 2,000 x g for 5 min. Serum samples were immediately measured for 
total serum bilirubin (TSB) levels using a Unistat Bilirubinometer (Reichert, Inc.).  
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Reverse Transcription Quantitative-PCR  
Tissue samples were homogenized in 0.5 mL TRIzol (Invitrogen, Waltham, 
MA) and total RNA from whole tissues was isolated using TRIzol reagents per the 
manufacturer’s instructions. Using iScript Reverse Transcriptase (Bio-Rad 
Laboratories, Hercules, CA), 1 μg of total RNA was used for the generation of cDNA 
in a total volume of 20 μL as outlined by the manufacturer. Following cDNA 
synthesis, quantitative PCR was carried out on a CFX96 qPCR system (BioRad) by 
using SsoAdvanced SYBR Green Supermix (BioRad). Primers were designed 
through the mouse primer depot (https://mouseprimerdepot.ncimci.nih.gov/). The 
sequences of the primers used are listed in Table 1.  
Western blot analysis  
Tissues (0.1 mg) were homogenized in 0.5 mL 1 x RIPA lysis buffer (EMD 
Millipore, Billerica, MA) supplemented with protease inhibitor cocktail (Sigma-Aldrich). 
Western blots were performed by using NuPAGE 4-12 % BisTris-polyacrylamide gels 
(Invitrogen) with the protocols described by the manufacturer. Protein (20 μg) was 
electrophoresed at 200 V for 50 min and transferred at 30 V for 2 hours to PVDF 
membranes (EMD Millipore). Membranes were blocked with either 5% skim milk or 
5% BSA (fraction V) at room temperature for 1 hour and incubated with primary 
antibodies (rabbit antihuman UGT1A1 (ab 194697), mouse anti-GAPDH (sc-47724), 
rabbit anti-CYP2B9/10 antibody, rabbit anti-p-p38 (cs-9211) or rabbit anti-p38 (cs-
9212)) at 4℃ overnight. Membranes were washed and exposed to HRP-conjugated 
secondary antibodies (anti-mouse IgG or anti-rabbit IgG) for 1 hour at room 
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temperature. Protein was detected by the ECL Plus Western blotting detection 
system (PerkinElmer) and was visualized by the BioRad gel documentation system. 
All Western blots are cropped from the full length blots that have been included in the 
Supplemental Material.  
Statistical analysis  
  Statistical significances were determined by analysis of variance by using 
Student’s t test. P values <0.05 were considered statistically significant, and 
statistically significant differences are indicated with *, P<0.05; **, P<0.01; 
***P<0.001.  
Table 1. Primer sequences used for Reverse Transcription Quantitative PCR (RT-
qPCR)  
Gene Forward (5’→3’) Reverse (5’→3’) 
Akp3  CTGGAGCCCTACACCGACT AGGCTTCTGGCGCTGTTAT 
Cph  CAGACGCCACTGTCGCTT TGTCTTTGGAACTTTGTCTGC 
Cyp2b10  AAAGTCCCGTGGCAACTTCC CATCCCAAAGTCTCTCATGG 
Glb1  CACTGCTGCAACTGCTGG ATGTATCGGAATGGCTGTCC 
GstA1  AGCCCGTGCTTCACTACTTC TCTTCAAACTCCACCCCTGC 
GstA2  GAATCAGCAGCCTCCCCAAT TCCATCAATGCAGCCACACT 
hUGT1A1  CCTTGCCTCATCAGAATTCCTTC ATTGATCCCAAAGAGAAAACCAC 
Krt20  CCTGCGAATTGACAATGCTA CCTTGGAGATCAGCTTCCAC 
Lrp2  CCAGGATTCTGGTGATGAGG CGGGAACTCCATCACAAACT 
Nox4  TCTGGAAAACCTTCCTGCTG CCGGCACATAGGTAAAAGGA 
Nqo1  TTTAGGGTCGTCTTGGCAAC GTCTTCTCTGAATGGGCCAG 
Sis  ACCCCTAGTCCTGGAAGGTG CACATTTTGCCTTTGTTGGATGC 
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RESULTS  
Impact of PEITC in neonatal hUGT1 mice.  
We have shown previously that xenobiotic induction of either gastrointestinal 
(GI) tract or liver UGT1A1 will promote the reduction of total serum bilirubin (TSB) in 
neonatal hUGT1 mice58,69. The impact of oral PEITC treatment to neonatal mice 
would be expected to induce ARE target genes both in the GI tract as absorption is 
occurring as well as in the liver prior to movement of PEITC into the systemic 
circulation. After a single oral dose of 200 mg/kg to 10-day-old hUGT1 mice, TSB 
levels were reduced to normal levels after 48 hours (Fig. 3A), indicating that UGT1A1 
was induced. Analysis of gene expression and protein in small intestine (SI) and liver 
shows induction of UGT1A1 (Fig. 3B and 3C). Target genes of the antioxidant 
response, Nqo1, Gsta1 and Gsta2 were not induced dramatically in either tissue (Fig. 
S1), indicating that an alternative mechanism other than an antioxidant response was 
underlying the induction of UGT1A1. Analysis of additional potential gene expression 
differences that might exist between liver and SI following PEITC administration 
confirmed induction of the Cyp2b10 gene and protein expression in both tissues (Fig. 
4), an observation that implicates a role for CAR in the induction process.  
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Figure 3. Induction of UGT1A1 by PEITC in neonatal hUGT1 mice. Ten day old 
neonatal hUGT1 mice were treated with 200 mg/kg PEITC or vehicle by p.o. 
administration. (A) On the second day, total serum bilirubin (TSB) levels were taken. 
(B) Liver and small intestine (SI) were pulverized under liquid nitrogen and used for 
the preparation of total RNA or whole tissue extracts. From RNA preparations, 
UGT1A1 gene expression was determined by real time PCR and expressed as fold 
induction. (C) Using whole tissue extracts, Western blots were performed from liver 
and SI tissue to examine UGT1A1 expression and imaged on a BioRad ChemiDoc 
Touch Imaging System. The bands have been cropped from the full-length blots but 
not enhanced in anyway (Fig. S4). Values are the means of ± SD (n>3). Statistically 
significant differences between vehicle (Veh) and PEITC are indicated by asterisks 
(Student t test: **, P<0.01).  
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Figure 4. PEITC induction of CYP2B10 in neonatal hUGT1 mice. Following the 
treatment of neonatal hUGT1 mice with 200 mg/kg PEITC for three days (see Figure 
1), Cyp2b10 gene and CYP2B10 protein expression were analyzed. (A) Using RNA 
isolated from liver and small intestines (SI), mRNA induction was quantitated by real 
time PCR. (B) Total tissue extracts prepared from the same tissues were used for 
Western blot analysis to examine CYP2B10 expression. The bands have been 
cropped from the full-lenth blots but not enhanced in anyway (Fig. S5). Values are 
the means of ± SD (n>3). Statistically significant differences between vehicle (Veh) 
and PEITC are indicated by asterisks (Student t test: *, P<0.05;).  
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To examine the possibility that CAR is playing a role following exposure to 
PEITC, 10-day-old hUGT1/Car-/- mice were treated orally with PEITC and analysis of 
both TSB levels, UGT1A1 and CYP2B10 expression were monitored in both liver and 
SI (Fig. 5). TSB levels were completely reduced in hUGT1/Car+/- mice and 
significantly reduced in hUGT1/Car-/- litter mates but were not as low as those 
observed in hUGT1/Car+/- mice (Fig. 5A). Deletion of CAR led to the complete lack of 
PEITC initiated induction of CYP2B10 and UGT1A1 expression in liver (Fig. 5B), 
confirming that PEITC exposure activates liver CAR. When we examined SI, 
CYP2B10 expression was absent in hUGT1/Car-/- mice, but induction of UGT1A1 
was observed (Fig. 5B). When gene expression patterns were examined in liver, 
induction of Cyp2b10 and UGT1A1 gene expression was absent in hUGT1/Car-/- 
mice, confirming the role of CAR in activation of these genes in hepatic tissue (Fig. 
5C). Intestinal tissue showed a different induction pattern. The Cyp2b10 gene was 
regulated in concordance with PEITC activation of CAR, showing no activation of the 
gene in hUGT1/Car-/- mice. In contrast, PEITC initiated induction of UGT1A1 gene 
expression equally in the SI of both hUGT1/Car+/- and hUGT1/Car-/- mice (Fig. 5D), a 
finding that would suggest the induction of UGT1A1 in intestinal tissue is being 
controlled by an alternate mechanism that is not linked to CAR activation.  
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Figure 5. PEITC induction in hUGT1/Car-null mice. Litters were bred to produce 
hUGT1/Car-/- and hUGT1/Car+/- mice and 10-day old neonatal mice treated with 200 
mg/kg on day 10, followed by TSB analysis and tissue preparation on day 12. (A) 
After treatment, TSB levels were quantitated in hUGT/Car+/- (car+/-) and hUGT1/Car-/- 
(car-/-) mice. (B) Using total cell extracts from liver and small intestines (SI), Western 
blots were performed using antibodies toward human UGT1A1 and mouse 
CYP2B10. The bands have been cropped from the full-length blots but not enhanced 
in anyway (Fig. S6). (C) Total RNA was prepared from liver and small intestines and 
mRNA expression determined by real time PCR. Values are the means of ± SD 
(n>3). Statistically significant differences between vehicle (Veh) and PEITC are 
indicated by asterisks (Student t test: *, P<0.05; **, P<0.01). 
 
 
To examine this possibility in greater detail, we undertook a series of 
experiments to determine if an oxidative stress response could be induced in the 
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intestines. We have shown previously that oral arsenic (As3+) exposure to neonatal 
hUGT1 mice induce Cyp2b10 and UGT1A1 gene expression69. If we treat neonatal 
hUGT1 mice with As3+ and measure phosphorylated p38 mitogen-activated protein 
kinase (MAPK) and extracellular signal-regulated kinase (ERK) activation, both 
markers of oxidative stress70, induction is observed as early as 2 hours after 
treatment (Fig. 6A). N-acetylcysteine (NAC), which serves as a precursor to elevate 
intracellular GSH71, blocks the effects of oxidative stress. We treated 10-day old 
hUGT1 mice with oral NAC and then challenged the mice with oral As3+, measuring 
gene expression after 24 hours. Arsenic treatment lead to a dramatic reduction in 
TSB levels that was blocked when the mice were pretreated with NAC. Arsenic 
induced UGT1A1, Cyp2b10 and Gsta1 gene expression, all of which were inhibited 
by NAC treatment (Fig. 6B). When we measured phosphorylated p38 MAPK after 
PEITC treatment as an index of oxidative stress, there was a rapid and sustained 
activation of p38 MAPK even through 24 hours (Fig. 6C), demonstrating that PEITC 
elicited a strong oxidative stress response in intestinal tissue. This was also verified 
by an increase in GSSG in intestinal tissue (Fig. S2). However, this response was 
not sufficient to activate Nrf2 target genes (Fig. S1).  
It has recently been demonstrated that nuclear receptor corepressor 1 
(NCoR1) in intestinal epithelial tissue controls neonatal intestinal maturation by 
repressing gene expression67. When NCoR1 is deleted by targeted gene interruption 
in intestinal tissue, epithelial cell maturation is accelerated in neonatal hUGT1 mice 
resulting in derepression of UGT1A1 gene expression with the near complete 
reduction in TSB levels. Intestinal epithelial cell (IEC) maturation can be analyzed by 
28 
 
measurement of IEC specific maturation markers, such as the upregulated Sis, Akp3, 
and Krt20 genes, and the downregulated Glb1, Nox4 and Lrp2 genes. Intestinal 
maturation can be induced by activated cellular kinases, which are believed to target 
phosphorylation of NCoR1 leading to derepression of gene expression72. Since 
PEITC is a potent inducer of intestinal p38 MAPK, we examined these maturation 
marker genes (Fig. 6D). Regulation of these genes followed closely the patterns of 
expression that were documented during neonatal intestinal maturation by expressed 
IKKβ and following targeted deletion of NCoR167. The possibility exists that the sharp 
increase in oxidative stress by PEITC promotes intestinal maturation, leading to 
derepression of the UGT1A1 gene and the reductions we have observed in TSB 
levels.  
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Figure 6. Induction of oxidative stress induces UGT1A1 in intestinal tissue. 
Neonatal hUGT1 mice were given a dose of either arsenic (As3+) or PEITC and 
markers of oxidative stress determined. (A) Ten day old mice were given a single oral 
dose of As3+ (10 mg/kg) and tissue extracts from the small intestine prepared after 4 
hours. Western blots were prepared and phosphorylated p38 MAPK and ERK 
determined. The bands have been cropped from the full-length blots but not 
enhanced in anyway. (B) Ten day old mice were pre-treated with 75 mg/kg N-
acetylcysteine (NAC) for one hour prior to As3+ exposure. Forty-eight hours after oral 
As3+ exposure, RNA was isolated from small intestine and RTqPCR was conducted 
for UGT1A1, Cyp2b10 and Gsta1 expression. Data is shown as fold induction of the 
value observed in mice treated with As3+ and water. (C) Ten-day-old mice were given 
an oral dose of PEITC (200 mg/kg) and intestinal tissue isolated at 0, 2, 5, and 24 
hours after treatment. Western blots were performed to examine activation of 
phosphorylated p38 MAPK (Fig. S7). (D) Twenty-four hours after PEITC treatment, 
RNA was prepared from small intestines and RT-qPCR performed to examine 
intestinal maturation marker gene expression. Genes Sis, Akp3 and Krt20 are 
upregulated during maturation while genes Glb1, Nox4 and Lrp2 are downregulated. 
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Impact of PEITC in adult hUGT1 mice  
  To examine the association of CAR activation and the anti-oxidative response 
in adult mice, we treated hUGT1/Car+/- and hUGT1/Car-/- mice orally with PEITC and 
evaluated gene and protein expression in liver and SI (Fig. 7). As observed in 
neonatal hUGT1 mice, PEITC led to induction of UGT1A1 and Cyp2b10 gene 
expression in liver as well as SI in hUGT1/Car+/- mice. Protein expression paralleled 
the findings of gene expression, with Western blots confirming induction of UGT1A1 
and CYP2B10 in liver and SI. The induction of CYP2B10 in liver is completely 
dependent upon CAR, since no induction was noted in hUGT1/Car-/- mice (Fig. 7A). 
There was also a dramatic reduction in the induction of UGT1A1 in hUGT1/Car-/- 
mice, implicating an important role for CAR in PEITC activation. However, we did 
detect both at the mRNA and protein level minor induction of UGT1A1 in hUGT1/Car-
/- mice, indicating that an alternative mechanism exists. Analysis of Nrf2 target genes 
confirmed induction was taking place by an oxidative stress response (Fig. S3). In 
the SI, PEITC treatment led to induction of the UGT1A1 gene and protein expression 
in both hUGT1/Car+/- and hUGT1/Car-/- mice (Fig. 7B). We have confirmed that 
PEITC does activate CAR in the SI, as shown by CAR dependent activation of the 
Cyp2b10 gene. While UGT1A1 is also a target following CAR activation by PEITC, 
the ability to induce UGT1A1 in hUGT1/Car-/- mice indicates that in this tissue the 
actions of PEITC are activating UGT1A1 gene expression and protein induction 
through an alternative signaling pathway. Since ARE genes are induced in the SI 
following treatment with PEITC (Fig. S3), it is reasonable to assume that an 
antioxidant response by PEITC is initiating induction of UGT1A1 in the SI.  
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Figure 7. Induction by PEITC in adult hUGT1/Car-/- mice. Adult (8 week) 
hUGT1/Car-/- and hUGT1/Car+/- mice were treated by p.o administration with 200 
mg/kg/day for three days. After treatment, RNA and total cell extracts were prepared. 
(A) From liver tissue, UGT1A1 and Cyp2b10 gene expression was analyzed by real 
time PCR and expressed as Fold induction. From the same tissues, total cell extracts 
were combined and used for Western blot analysis using anti-human UGT1A1 and 
anti-mouse CYP2B10 antibodies. The bands have been cropped from the full-length 
blots but not enhanced in anyway (Fig. S8). (B) From small intestine, a similar series 
of experiments were performed. Values are the means of ± SD (n>3). Statistically 
significant differences between vehicle (Veh) and PEITC are indicated by asterisks 
(Student t test: *, P<0.05).  
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The role of oxidative stress and control of CAR.  
To separate an anti-oxidative response initiated by PIETC from activation of 
CAR and induction of UGT1A1, we first administered adult hUGT1 mice N-
acetylcysteine (NAC) in their drinking water for 2weeks. NAC prevents oxidative 
damage in tissues and cells by altering the redox-state and provides a reducing 
environment by increasing intracellular glutathione concentrations71. After two weeks 
of NAC exposure, hUGT1 mice were administered PIETC. Examining liver, anti-
oxidant-generated gene expression patterns for Nqo1, Gsta1 and Gsta2, which were 
induced by PIETC, were blocked following NAC exposure (Fig. 8). Similarly, 
induction of gene expression for both liver UGT1A1 and Cyp2b10 by PEITC was 
inhibited because of NAC treatment (Fig. 8B). For UGT1A1 expression, NAC 
exposure completely blocked PEITC induction of UGT1A1. These results indicate 
that by replenishing intracellular antioxidant glutathione levels, NAC blocked PIETC-
medicated antioxidant responses, and more surprisingly, abolished induction of both 
Cyp2b10 and UGT1A1 gene expression. These findings strongly suggesting that the 
Nrf2-ARE signaling pathway is actively involved in regulating these genes. Since we 
have demonstrated in liver that induction of the Cyp2b10 and UGT1A1 genes is 
driven by activation of CAR following PIETC exposure, this finding indicates that 
there is an important association between the production of ROS by PIETC and 
activation of CAR.   
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Figure 8. Impact of N-acetylcysteine on PEITC induction of UGT1A1. N-
acetylcysteine (NAC) was added to the drinking water at a concentration of 40 mM 
for 3 weeks. After NAC exposure, adult hUGT1 mice were treated by p.o. 
administration with 200 mg/kg PEITC once each day for three days. Liver was 
isolated after PEITC treatment. (A) From total RNA, human UGT1A1 and mouse 
Cyp2b10 gene expression was determined by real time PCR. (B) Using total cellular 
lysates, UGT1A1 expression was determined by Western blot analysis. The bands 
have been cropped from the full-length blots but not enhanced in anyway (Fig. S8). 
(C) Nqo1, Gsta1 and Gsta2 gene expression by real time PCR. Values are means ± 
SD (n=3). Statistically significant differences between Vehicle (Veh) and PEITC are 
indicated by asterisks (Student t test: *, P< 0.05)  
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DISCUSSION  
The antioxidant initiated induction patterns following exposure to PEITC have 
been shown to result from activation of the transcription factor Nrf2 that leads to its 
binding to ARE elements followed by transcriptional activation73–75. Activation of the 
Nrf2-Keap1 pathway in response to chemical and oxidative stress leads to the 
induction of a host of cytoprotective enzymes that provide an active defense 
mechanism against cellular damage. This unique signaling pathway was first 
discovered when ARE sequences were identified on two genes that encode enzymes 
involved in detoxification processes, NQO176 and GSTA277. The Nqo1 and Gsta2 
genes are induced through the ARE elements following exposure to H2O2 and other 
agents that undergo redox cycling, or by compounds that are electrophilic. Other 
agents, such as the isothiocyanate PEITC, react with sulfhydryl groups to elevate the 
levels of ROS and reduce the antioxidant capacity, which in turn trigger the 
transcriptional response mediated by the AREs. Other genoprotective genes 
associated with cellular detoxification processes, such as UGTs, have long been 
implicated as important target genes that are induced following chemical and 
oxidative stress. A cluster of ARE elements in the phenobarbital response enhancer 
module (PBREM) in the UGT1A1 gene has been identified and promotes Nrf2 
dependent transcriptional activation66. Based upon these findings, it would be an 
obvious assumption that induction of the human UGT1A1 gene following PEITC 
exposure would result from the production of an antioxidant response.  
The previous development of hUGT1 mice offered us the opportunity to 
examine activation of the UGT1A1 gene since chemicals or agents administered to 
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neonatal hUGT1 mice that result in the reduction of TSB levels are directly inducing 
UGT1A1 expression58,60,69,78,79. When PEITC was administered orally to neonatal 
hUGT1 mice, within 24 hours the TSB levels were reduced to those measured in wild 
type mice. Induction of UGT1A1 gene and protein expression is significant in both SI 
and liver, indicating that a prominent antioxidant response was initiated following 
PEITC dosing. However, there was no significant induction of other key antioxidant 
target genes related to the Nrf2 signaling pathway, such as Nqo1, Gsta1 or Gsta2, 
leaving us to speculate that induction of UGT1A1 was occurring independently from a 
Nrf2-medicated antioxidant response in the neonatal mice, although we would not 
rule out the possibility that Nrf2 is not fully activated at our experimental dose. 
Examination of additional gene expression patterns confirmed that PEITC 
dramatically induced Cyp2b10 gene and protein expression in both SI and liver, an 
important target gene that is regulated following activation of CAR. When we 
extended these experiments to examine the impact of oral PEITC on TSB levels and 
UGT1A1 expression in neonatal hUGT1/Car-/- mice, TSB levels were reduced. 
However, there was no induction of UGT1A1 or CYP2B10 in liver tissue, confirming 
that PEITC induction of the UGT1A1 and Cyp2b10 genes in neonatal hUGT1 mice 
are CAR dependent. While intestinal Cyp2b10 gene expression is absent in neonatal 
hUGT1/Car-/- mice, we still observed induction of UGT1A1 gene expression, leaving 
us to conclude that the actions of PIETC and induction of UGT1A1 in SI were 
occurring independently of CAR.  
To examine this possibility, we first looked at the possibility of As3+, a known 
activator of oxidative stress and potent inducer of neonatal UGT1A1 and CYP2B1069, 
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to activate stress linked proteins such as p38 MAPK. Oral As3+ rapidly activated 
phosphorylated p38 MAPK, demonstrating that oxidative stress was induced. When 
this process was blocked by pre-treatment with NAC, induction of UGT1A1 gene 
expression and the reduction in TSB values were blocked. This experiment indicated 
that activation of cellular kinases by oxidative stress may contribute to induction of 
intestinal UGT1A1. When we administered PEITC to neonatal hUGT1 mice, intestinal 
phosphorylated p-38 MAPK was dramatically activated at least through 24 hours. 
Recent experiments conducted in our laboratory have confirmed that derepression of 
NCoR1 in neonatal intestinal tissue results in activation of intestinal maturation and 
the induction of UGT1A167. This process may be linked to the actions of PEITC since 
the mechanism that leads to NCoR1 derepression requires direct phosphorylation80, 
an event that may be linked to PEITC activated p38 MAPK. This possibility is 
supported by analysis of maturation gene expression profiles, an event that we have 
shown leads to induction of intestinal UGT1A1 and a reduction in TSB levels67.  
In adult mice, PEITC administration led to prominent induction of UGT1A1 and 
CYP2B10 in liver and SI tissue, but there was a clear dominance of the induction 
pattern in liver. In contrast to induction patterns characterized in neonatal hUGT1 
mice, PEITC treatment to adult mice led to significant induction of an antioxidant 
response as confirmed by induction of target genes Nqo1, Gst1a and Gsta2.  
However, deletion of CAR in adult hUGT1/Car-/- mice resulted in the elimination of 
both UGT1A1 and Cyp2b10 gene induction by PEITC, confirming previous findings 
that induction of these genes is dependent upon CAR. Collectively, these results 
indicate that PEITC has dual effects on activating both CAR and Nrf2, conveying its 
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antioxidant activity by inducing cellular detoxification processes – including the phase 
I Cyp2b10 and phase II, UGT1A1, Nqo1, Gsta1 and Gsta2 genes. These genes are 
regulated in an age- and tissue-specific fashion by PEITC with different modes of 
actions: Following PEITC treatment, CAR appears to be the dominant regulator in 
CYP2B10 induction, whereas activation of both CAR and Nrf2 is associated with 
UGT1A1 induction. In line with these results is the evidence that the PBREM but not 
the ARE region has been identified in the Cyp2b10 promoter12, although it has 
recently been suggested that Nrf2 is involved in phorone induction of Cyp2b1081. In 
contrast, both response elements have been proven to be functional and located 
adjacent to each other within UGT1A1 promoter sequences66. In addition, in 
neonates CAR has a preferential role in regulating UGT1A1, and the Nrf2-antioxidant 
pathway becomes more responsive to PEITC as mice reach maturity. Although liver 
and SI tissues generally exhibit similar induction patterns responding to PEITC 
exposure, our results suggest that induction of hepatic UGT1A1 is predominantly 
regulated by CAR, and its expression in SI may be attributed to both CAR and Nrf2.   
To isolate the antioxidant response from CAR dependency in PEITC induction 
of UGT1A1 and CYP2B10, we exposed adult hUGT1 mice to NAC to block PEITC 
induced ROS production. Addition of the free radical scavenger NAC led to not only 
the complete inhibition of PEITC-induced expression of antioxidant genes Nqo1, 
Gsta1 and Gsta2 but also the blockage of CAR-initiated induction of the UGT1A1 and 
Cyp2b10 genes. This finding is significant because it indicates PEITC is the source of  
ROS enhanced expression of the UGT1A1 and Cyp2b10 genes through a ROS-
dependent mechanism, further supporting the involvement of redox-sensitive 
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transcription factor Nrf2 in controlling expression of UGT1A1 and CYP2B10. In 
combination with our findings that CAR is essential for PEITC initiated induction of 
UGT1A1, NAC blocks the PEITC induced antioxidant response, impacting induction 
of UGT1A1 and Cyp2b10 gene expression, suggesting an interaction between 
PEITC-produced oxidative stress and CAR activation, however the mechanism 
underlying the crosstalk between CAR and Nrf2 still needs to be determined. An 
outline of the proposed mechanism of PEITC initiated induction of the Cyp2b10 and 
UGT1A1 genes in liver and small intestine is outlined in Fig. 9.  
 
Figure 9. The actions of PIETC and regulation of UGT1A1 gene expression. 
Consumption of cruciferous vegetables leads to the generation of reactive oxygen 
species (ROS). The ROS generates signals that leads to the activation Nrf2, 
facilitating an ARE response on susceptible target genes. In addition, ROS are linked 
to the activation of CAR in both liver and small intestines, which leads to the induction 
of Cyp2b10 and UGT1A1. In neonatal mice, it is also predicted that ROS has the 
potential to induce intestinal tissue maturation, an event that has been shown to 
induce the UGT1A1 gene. The induction of UGT1A1 in either the liver or small 
intestine will promote the metabolism and elimination of serum bilirubin. The addition 
of N-acetylcysteine (NAC) blocks the ROS response, nullifying both CAR and Nrf2 
activation.  
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In adult hUGT1 mice, PEITC exposure produces an antioxidant response in 
both liver and SI, but the same response is not achieved in neonatal hUGT1 mice. 
Bilirubin is a natural antioxidant when bound to albumin34 and slightly elevated levels 
in individuals that inherit Gilbert’s syndrome have been documented to have reduced 
rates of cardiovascular disease in addition to certain cancers33. Hence, the elevated 
concentrations of TSB in neonatal hUGT1 mice may be sufficient to prevent PEITC 
induced ROS production, which is necessary to initiate an antioxidant response. 
When maternal mice were administered a daily dose of PEITC, nursing pups 
demonstrated a reduction in TSB levels (data not shown). The reduction in TSB 
levels correlated with induction of intestinal UGT1A1 expression. These findings 
indicate that neonatal hyperbilirubinemia can possibly be controlled through a 
maternal diet.  
Our studies indicate that certain dietary ingredients present in cruciferous 
vegetables have a beneficial effect by providing a reductive capacity in tissues while 
also controlling important detoxification pathways such as glucuronidation, which are 
controlled at the transcriptional level through multiple signaling pathways. In addition 
to the important antioxidant response that leads to activation of the Nrf2-Keap1 
pathway, we show here that ITCs regulate significant gene expression through a 
CAR dependent mechanism. However, the CAR dependent induction process, which 
we show exists for both the human UGT1A1 gene and the murine Cyp2b10 gene, 
appears to be linked mechanistically with a controlled antioxidant response. This 
relationship between CAR and Nrf2, which are both activated by PEITC, may serve 
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as a double-edged-sword with regards to liver disease. Under these circumstances, 
agents that activate CAR stimulate the proliferative process and serve as tumor 
promotors82. Recently, it has been demonstrated that the accumulation of p62, a 
protein that can activate multiple signaling pathways, is induced in liver disease such 
as liver fibrosis and HCC. Induction of p62 leads to the activation of Nrf2, and 
sustained Nrf2 activation has been shown to be oncogenic83. Thus, in situations of 
liver disease, a diet rich in cruciferous vegetables would promote tumorigenesis 
through the activation of CAR while stimulating additional oncogenesis by activation 
of Nrf2. While a diet that includes cruciferous vegetables is believed to promote 
health by activating cellular defense systems, their consumption following liver 
disease may be detrimental.  
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Chapter 2, in part, is an inexact reprint of the material as it appears in the 
following: Yoda E, Paszek M, Konopnicki C, Fujiwara R, Chen S, and Tukey RH 
(2017) Isothiocyanates induce UGT1A1 in humanized UGT1 mice in a CAR 
dependent fashion that is highly dependent upon oxidative stress. Scientific Reports 
Vol 7. The dissertation author was the second investigator and author of this paper. 
Changes to the material presented were made to maintain format consistency. 
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CHAPTER 3: NRF2-INDEPENDENT REGULATION OF CAR BY OXIDATIVE 
STRESS 
Taken from: Paszek M and Tukey RH. (2020) NRF2-independent regulation of 
intestinal constitutive androstane receptor by the pro-oxidants cadmium and 
isothiocyanate in hUGT1 mice. Drug Metab. Dispos. Vol. 48, Issue 1. 25-30. 
Abstract 
Environmental toxicants such as heavy metals from contaminated water or soil 
and isothiocyanates (ITC) from dietary sources act as pro-oxidants by directly 
generating reactive oxygen species (ROS) or through depleting cellular antioxidants 
such as glutathione. Toxicants can alter drug metabolism and it was reported that 
CYP2B10 and UGT1A1 are induced by phenethyl isothiocyanate (PEITC) through 
the constitutive androstane receptor (CAR). The possibility that NRF2, the master 
regulator of the antioxidant response, could co-activate CAR was investigated in 
neonatal hUGT1/Nrf2-/- mice. Neonatal mice were treated with PEITC or cadmium 
(Cd2+) by oral gavage for two days. Both PEITC and Cd2+ induced UGT1A1 RNA and 
protein in intestinal tissues in both hUGT1/Nrf2+/- and hUGT1/Nrf2-/- neonates, 
indicating NRF2-independent regulation of UGT1A1. Increases in CYP2B10 RNA in 
intestinal tissues were observed following PEITC or Cd2+ exposure. Activation of 
intestinal CAR by Cd2+ exposure was directly assessed by nuclear fractionation and 
Western blot analyses at 0.5, 1, 2, and 4 hours after treatment in hUGT1 neonates 
and after 48 hours in hUGT1/Nrf2+/- and hUGT1/Nrf2-/- neonates. CAR localized to 
the nucleus independent of NRF2 48 hours after exposure. Substantial CAR 
localization to the nucleus occurred at the 2- and 4-hour time points, coinciding with a 
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decrease in cytoplasmic ERK1/2 phosphorylation and a nuclear increase in P38/p-
P38 content. This suggests a novel oxidative stress-MAPK-CAR axis exists with 
phenotypic consequences. 
Significance Statement 
Pro-oxidant toxicants can alter drug metabolism through activation of CAR, 
independent of the NRF2-KEAP1 signaling pathway. The changes in proteins 
associated with drug metabolism are likely mediated through an oxidative stress-
MAPK-CAR axis that have been linked to increases in intestinal maturation. 
Introduction 
Exposure to certain environmental toxicants is capable of altering drug 
metabolism through the activation of selective transcription factors, such as 
xenobiotic and nuclear receptors (XRs and NRs). The activation of XRs and NRs 
typically occurs through direct ligand binding to the receptor or through post 
translation modifications. In vitro models enable medium- to high- throughput 
screening of compounds abilities to activate nuclear receptors while in vivo models 
provide more complex details such as absorption, elimination, and tissue specific 
metabolism.  
An in vivo model that lends itself well to reverse genetic approaches is the 
humanized UDP-glucuronosyltransferase 1 (hUGT1) mouse model due to the readily 
quantifiable phenotype that changes following XR or NR activation 37,58,60. The 
phenotype is presented as neonatal hyperbilirubinemia, a condition unique to 
humans in which increased turnover of red blood cells causes heme degradation to 
bilirubin which, accumulates systemically 84. The accumulation of bilirubin occurs 
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because hepatic expression of UGT1A1, the only enzyme capable of conjugating 
bilirubin for excretion 61, is developmentally delayed at the transcriptional level 85. 
However, we have demonstrated that control of intestinal UGT1A1 during 
development plays a key role in the clearance of serum bilirubin during the neonatal 
period 69,86. Induction of the UGT1A1 gene in hUGT1 mice can be mediated by 
multiple XRs and NRs, such as the pregnane X-receptor (PXR) 79, constitutive 
androstane receptor (CAR) 87, peroxisome proliferator-activated receptor α (PPARα) 
38, as well as environmental toxicant sensors such as the aryl hydrocarbon receptor 
(AhR) 65,88, and the nuclear factor erythroid 2-related factor 2 (NRF2) 66. Following 
exposure, activation of one or more of these XRs and NRs induces UGT1A1 gene 
expression resulting in a reduction of total serum bilirubin (TSB) levels 37,89. Known 
transcriptional targets can be examined to determine which XR or NR is inducing 
UGT1A1, for example CAR induces the Cyp2b10 90 gene while activated NRF2 can 
induce genes such as Gsta1/2 91, which are sensitive to oxidative stress. The 
receptor mediated induction of UGT1A1 can be confirmed in neonatal hUGT1 mice 
that express a null allele for the XRs or NRs, where elevated TSB levels following 
exposure can be directly linked to a dependency on the deleted receptor 69,92,93.  
Recently, it was reported that the dietary pro-oxidants isothiocyanates (ITCs) 
induce hepatic UGT1A1 in a CAR-dependent fashion 93. This is significant because 
the mechanisms of direct and indirect activation of CAR are well characterized 24–26,94 
but have never directly implicated oxidative stress as a CAR activator. Additionally, 
other environmentally relevant toxicants, such as cadmium (Cd2+) and arsenic (As3+) 
that increase reactive oxygen species (ROS) have been reported to induce intestinal 
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Cyp2b10 and UGT1A1 gene expression in hUGT1 mice 60,93. However, UGT1A1 
induction by pro-oxidants has been linked to NRF2 66, the master regulator of the 
antioxidant response 95. The induction mechanism of intestinal UGT1A1 in hUGT1 
mice by agents such as Cd2+, ITCs, and As3+ are examined with respect to their link 
towards activation of NRF2 and CAR. 
Materials and Methods 
Animal Studies. 
All animals were housed at the University of California San Diego Animal Care 
Facility with access to food and water ad libitum. All animal use including 
experimental procedures, handling, and protocols were approved by the UCSD 
Animal Care and Use Committee (IACUC) and adhere to the National Institute of 
Health Guide for the Care and Use of Laboratory Animals. UCSD’s Animal Care 
Program is accredited by the Association for the Assessment and Accreditation of 
Laboratory Animal Care (AAALAC). Humanized UGT1 (hUGT1) mice were previously 
generated as described. Nrf2-/- mice were purchased from Jackson Laboratory (Stock 
No: 017009), and hUGT1/Nrf2+/- mice were generated and crossed for comparison to 
hUGT1/Nrf2+/+ mice, utilizing both males and females. Additional studies involved 
breeding hUGT1/Nrf2+/- with hUGT1/Nrf2-/- to generate male and female mice used 
for neonatal studies. Neonates were treated on day 10 and 11 with CdCl2·2 ½ H2O 
(Cd2+) or NaAsO2 (As3+) (Sigma-Aldrich) at 10mg/kg or PEITC (Sigma Aldrich) at 200 
mg/kg by oral gavage or with water or corn oil (5μL/g bw) for vehicle control. The 
dosages for CdCl2 and PEITC treatments were selected from dose-response curves 
where both the greatest reduction in total serum bilirubin levels and no observable 
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behavioral or gross anatomical phenotypes of toxicity were obtained. Animals were 
anesthetized with isoflurane and euthanized by cervical dislocation. 
Real-time PCR. 
Intestines were collected and briefly washed with ice cold PBS 3 times before 
snap freezing in liquid nitrogen. Livers were collected and washed once with ice cold 
PBS before snap freezing in liquid nitrogen. RNA was extracted with TRIzolTM 
Reagent (ThermoFisher Scientific) as described by the manufacturer’s protocol. 
cDNA was synthesized using iScriptTM cDNA Synthesis Kit (Bio-Rad) according to 
the manufacturer’s protocol. Real-time PCR was performed using a CFX96TM Real-
Time PCR Detection system (Bio-Rad) and SSoAdvancedTM Universal SYBR® Green 
Supermix (Bio-Rad) as described by the manufacturer’s protocol. All values represent 
independent biological replicates and technical singlets as analyzed by the ∆∆CT 
method. Primers utilized for real time PCR analysis of selected genes can be found in 
Table 2. 
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Table 2. Primers utilized for real-time PCR analysis of selected genes  
Gene Forward (5’→3’) Reverse (5’→3’) 
Cph CAGACGCCACTGTCGCTT TGTCTTTGGAACTTTGTCTGC  
Cyp1a1 TGCCCTTCATTGGTCACATG CACGTCCCCATACTGCTGACT 
Cyp2b10 AAGGAGAAGTCCAACCAGCA CTCTGCAACATGGGGGTACT 
Cyp3a11 ACAAACAAGCAGGGATGGAC CCCATATCGGTAGAGGAGCA 
Cyp4a10 CACACCCTGATCACCAACAG TCCTTGATGCACATTGTGGT 
Glb1 CACTGCTGCAACTGCTGG ATGTATCGGAATGGCTGTCC 
Gsta1 AGCCCGTGCTTCACTACTTC TCTTCAAACTCCACCCCTGC 
Gsta2 AATCAGCAGCCTCCCCAAT TCCATCAATGCAGCCACACT 
Gstm3 AAACCTGAGGGACTTCCTGG AACACAGGTCTTGGGAGGAA 
Ho-1 ACAGGGTGACAGAAGAGGCTAAGAC ATTTTCCTCGGGGCGTCTCT 
hUGT1A1 CCATCATGCCCAATATGGTT CCACAATTCCATGTTCTCCA 
Il-1b GCAACTGTTCCTGAACTCAAC ATCTTTTGGGGTCCGTCAACT 
Il-6 ACCAGAGGAAATTTTCAATAGGC TGATGCACTTGCAGAAAACA 
Krt20 CCTGCGAATTGACAATGCTA CCTTGGAGATCAGCTTCCAC 
Lrp2 CCAGGATTCTGGTGATGAGG CGGGAACTCCATCACAAACT 
Nqo1 TTTAGGGTCGTCTTGGCAAC GTCTTCTCTGAATGGGCCAG 
Sis ACCCCTAGTCCTGGAAGGTG CACATTTTGCCTTTGTTGGATGC 
Tnfα GATCGGTCCCCAAAGGGATG GGCTACAGGCTTGTCACTCG 
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Western Blot Analysis. 
Whole lysate was obtained from homogenization of pulverized intestinal 
tissues in RIPA buffer (Millipore Sigma Cat. No. 20-188) containing protease 
(ThermoFisher ScientificTM Cat. No. 78429) and phosphatase (ThermoFisher 
ScientificTM Cat. No. 78420) inhibitors. Pulverized tissues in lysis buffer (1:4 wt/vol) 
were blade homogenized and incubated on ice for 15 min before centrifugation 
(10,000xg, 4°C, 20 min) and supernatant storage at -80°C.  
Nuclear fractionation used a two-buffer extraction. Buffer A contained 10mM 
HEPES, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, and 0.05% Igepal at pH 7.9 with 
protease and phosphatase inhibitors. Buffer B contained 5mM HEPES, 1.5mM 
MgCl2, 0.2mM EDTA, 0.5mM DTT, and 26% glycerol (v/v) at pH 7.9 with protease 
and phosphatase inhibitors. Pulverized tissues were homogenized in buffer A (1:4 
wt:vol) using a Potter-Elvehjem homogenizer for 10 passes. Homogenates were 
incubated on ice for 10 minutes prior to centrifugation (1500xg, 4°C, 10 min). The 
supernatant containing the cytosol was stored at -80°C. The pellet containing the 
nuclear contents was washed with 200uL of buffer A before resuspension in 400uL of 
Buffer B. After resuspension, NaCl was added to a final concentration of 300mM and 
the solution was sonicated for 5 sec and this repeated three times. Samples were 
incubated on ice for 30 minutes before centrifugation (21,000xg, 4°C, 20 min). The 
supernatant containing the nuclear fraction was stored at -80°C. Protein 
concentration was determined via Bradford assay (Bio-Rad), and BSA (New England 
BioLabs) protein standards were created for simple linear regressions. 
49 
 
Samples were run on NuPAGETM 4-12% Bis-Tris Protein Gels (Invitrogen) 
before transferring to PVDF membranes. Membranes were blocked with 5% nonfat 
milk or BSA for phospho-antibodies in TBST and incubated with primary antibodies 
overnight at 4°C and secondary antibodies for 1 hour at RT. Imaging was performed 
on a ChemiDocTM Touch imaging system (Bio-Rad) using ClarityTM Western ECL 
substrate (Bio-Rad). All antibodies used for protein expression and localization 
analyses can be found in Table 3. All samples represent biological replicates and 
technical singlets. 
Table 3. Antibodies utilized for Western blot analysis 
Antibody Supplier Product # 
Anti-mouse IgG, HRP-linked Cell Signaling Technology #7076 
Anti-rabbit IgG, HRP-linked Cell Signaling Technology #7074 
CAR ABclonal A1970 
ERK1/2 Cell Signaling Technology #9102 
Phospho-ERK1/2 Cell Signaling Technology #9101 
GAPDH Santacruz Biotechnology sc-47724 
HDAC-1 Santacruz Biotechnology sc-6298 
Histone 3 ABclonal A2352 
P38 Cell Signaling Technology #9212 
Phospho-P38 Cell Signaling Technology #9211 
Tubulin Sigma-Aldrich T9026 
UGT1A1 Abcam Ab170858 
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Bilirubin measurement. 
Approximately 50 μL of blood was obtained from the submandibular vein. 
Blood was centrifuged for 2 minutes at 16,000xg and the supernatant was measured 
using a Unistat Bilirubinometer (Reichert Inc.) to determine total serum bilirubin (TSB) 
levels. 
Statistical analysis 
All statistical analyses were performed using GraphPad Prism’s (V 6.07) two-
way ANOVA with multiple comparisons unless indicated otherwise. Averages +/- 
SEM are shown. Differences were considered statistically significant when p<0.05. 
Statistical significance is represented by the following: * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001.  
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Results 
Cadmium treatment induces oxidative stress markers in an NRF2-dependent 
manner  
 Intestinal tissues were collected from hUGT1/Nrf2+/+, hUGT1/Nrf2+/-, and 
hUGT1/Nrf2-/- neonates treated orally with 10mg/kg Cd2+ and gene targets known to 
be induced by NRF2 in response to oxidative stress examined by RT-qPCR (Fig. 10).  
 
Figure 10. NRF2-dependency of antioxidant response genes in neonatal hUGT1 
mice. Ten-day old hUGT1/Nrf2+/+, hUGT1/Nrf2+/-, and hUGT1/Nrf2-/- neonatal mice 
were treated with vehicle (blue circles) or Cd2+ (10mg/kg od. po.) (red squares) for 
two days before collecting intestinal tissue for RT-qPCR analysis of oxidative stress 
markers. The genes examined include Nqo1, Ho-1, Gsta1, Gsta2, and Gstm3. (Mean 
+/- SEM, Two-way ANOVA; * P<0.05, *** P<0.001, **** P<0.0001)  
 
Statistically significant inductions were detected in Cd2+ exposed 
hUGT1/Nrf2+/+ and hUGT1/Nrf2+/- neonates for Nqo1 (2.7- and 1.7-fold), Ho-1 (6.8- 
and 4.3-fold), Gsta1 (37.8- and 33.0-fold), Gsta2 (9.3- and 7.9-fold), and Gstm3 
(15.8- and 8.7-fold) genes. A gene dosage effect comparing responses between 
hUGT1 and hUGT1/Nrf2+/- neonatal mice was observed for the induction of the Nqo1, 
Ho-1, and Gstm3 genes. This indicates haploinsufficiency related to NRF2’s induction 
of antioxidant response genes. When we examined the induction of these genes in 
hUGT1/Nrf2-/- mice following Cd2+ treatment, there was no statistically significant 
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difference from the vehicle treatment of hUGT1 mice, confirming that the induction of 
these genes in the gastrointestinal tract originates from the generation of ROS in the 
intestines. With oral Cd2+ treatment, there was no induction of these genes in hepatic 
tissue. 
 
Cadmium induces intestinal UGT1A1 and lowers TSB levels in an NRF2 
independent fashion. 
It was previously determined that oral Cd2+ treatment to neonatal hUGT1 mice 
led to the induction of intestinal UGT1A1 69. To determine if induction of the intestinal 
UGT1A1 gene by Cd2+ was dependent upon the generation of ROS and activation of 
the NRF2-KEAP1 pathway, hUGT1/Nrf2+/- mice were mated and 10-day old 
newborns treated with 10mg/kg Cd2+ or water by oral gavage once per day for two 
days before collecting blood and intestinal tissue. With hUGT1, hUGT1/Nrf2+/-, and 
hUGT1/Nrf2-/- mice, Cd2+ treatment eliminated circulating TSB levels within two days, 
indicating that a mechanism had been activated to induce intestinal UGT1A1 (Fig. 
11A). 
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Figure 11. Cadmium reduces TSB levels in hUGT1 neonatal mice in an NRF2 
independent fashion. Ten-day old hUGT1/Nrf2+/+, hUGT1/Nrf2+/-, and hUGT1/Nrf2-/- 
neonatal mice were treated with vehicle (blue circles) or Cd2+ (10mg/kg od. po.) (red 
squares) for two days before collecting blood and intestinal tissues. (A) Changes in 
TSB levels (mg/dL) from mice treated with Cd2+. (B) Changes in the expression of the 
UGT1A1 gene. (C) Changes in the expression of the UGT1A1 protein as visualized 
by Western blot analysis and (D) quantified by normalizing to GAPDH expression and 
set relative to vehicle treated hUGT1/Nrf2+/- mice. (Mean +/- SEM, Two-way ANOVA; 
* P<0.05, ** P<0.01, **** P<0.0001) 
 
 Similar reductions were observed for PEITC and As3+ treated neonatal mice 
(Fig. S10). Analysis of UGT1A1 expression both at the gene and protein level firmly 
establish that Cd2+ exposure induces intestinal UGT1A1 (Fig. 2B and C). Unlike the 
Cd2+ initiated induction of the Nqo1, Ho-1, Gsta1, Gsta2, and Gstm3 genes (Fig. 10), 
which are dependent upon NRF2, induction of the intestinal UGT1A1 gene by Cd2+ is 
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not linked to the NRF2-KEAP1 pathway. It should be noted that an antioxidant-
response element (ARE) has previously been identified flanking the UGT1A1 gene in 
the phenobarbital-response enhancer module region (PBREM), and has been 
demonstrated to bind the antioxidant tert-butylhydroquinone (tBHQ) inducible NRF2 
in treated HepG2 cells 66. In addition, the intraperitoneal administration of tBHQ to 
adult TgUGT1 mice led to induction of intestinal UGT1A1, implicating the NRF2-
KEAP1 pathway as a regulator of the UGT1A1 gene 66. However, the oral 
administration of Cd2+ and induction of intestinal UGT1A1 in hUGT1 neonatal mice 
does not require NRF2-KEAP1 signaling.  
 
Intestinal Cyp2b10 is positively regulated by cadmium exposure and induces 
nuclear accumulation of CAR 
The nuclear receptors that induce UGT1A1 were examined for activation by 
RT-qPCR analysis of their known target genes (Fig. S11). Only Cyp2b10 was 
substantially induced by Cd2+ in hUGT1/Nrf2+/+ (8.4-fold), hUGT1/Nrf2+/- (13.5-fold), 
and hUGT1/Nrf2-/- (9.8-fold) neonates, however only heterozygotes reached 
statistical significance (Fig. 12A). Furthermore, Western blot analysis of CYP2B10 
was inconclusive with no apparent detection in either vehicle or Cd2+ treated mice. 
Given that basal expression of CYP2B10 in neonatal intestinal tissue is low, CAR 
activation was assayed more directly via nuclear localization.  
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Figure 12. NRF2-indendent changes of intestinal Cyp2b10 gene expression and 
CAR localization. Ten-day old hUGT1/Nrf2+/+, hUGT1/Nrf2+/-, and hUGT1/Nrf2-/- 
neonatal mice were treated with vehicle (blue circles) or Cd2+ (10mg/kg od. po.) (red 
squares) for two days before collecting intestinal tissues. (A) Changes in the 
expression of the Cyp2b10 gene were observed by RT-qPCR. (B) Nuclear 
localization of CAR was determined by Western blot analysis of fractionated intestinal 
protein extracts. (C) Expression of CAR was quantified by normalizing to HDAC-1 
and set relative to vehicle treated hUGT1/Nrf2+/-mice. (Mean +/- SEM, Two-way 
ANOVA; * P<0.05, ** P<0.01, *** P<0.001) 
 
Intestinal tissues taken from hUGT1/Nrf2+/- and hUGT1/Nrf2-/- neonates 
exposed to Cd2+ were fractionated and examined for nuclear CAR accumulation by 
Western blot analysis (Fig. 12B). There was a statistically significant increase in the 
nuclear accumulation of CAR in hUGT1/Nrf2+/- (3.7-fold) and in hUGT1/Nrf2-/- mice 
(1.8-fold) following exposure to Cd2+. This localization can occur independently of 
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NRF2 but is 2-fold less in hUGT1/Nrf2-/- compared to hUGT1/Nrf2+/- neonatal mice. 
This indicates that NRF2 is not responsible for the activation of CAR by Cd2+. 
 
In vivo Cd2+ exposure induces mitogen-activated protein kinase (MAPK) 
phosphorylation and CAR localization 
The regulation of CAR localization makes use of ERK1/2 and P38 
phosphorylation, which was examined by Western blot analysis. Neonatal hUGT1 
mice were treated orally with a single dose of Cd2+ (10mg/kg) or water and intestinal 
tissues were collected 30 minutes, 60 minutes, 120 minutes, and 240 minutes after 
exposure. Following treatment, the neonatal mice experienced dramatic changes in 
MAPK phosphorylation, where a large increase in cytoplasmic phosphorylated 
ERK1/2 occurs in intestinal tissue between 0 and 30 minutes after oral treatment 
before decaying (Fig. 13B). Additionally, there is an accumulation of P38 and 
phosphorylated-P38 in the nucleus (Fig. 13A). Similar phosphorylation patterns were 
observed in adult mice (data not shown). Consistent increases in CAR accumulation 
in the nucleus were observed in neonatal mice after 2 hours (Fig. 13C) coinciding 
with the dephosphorylation of ERK1/2 and the nuclear accumulation of P38. 
57 
 
 
Figure 13. Changes in intestinal MAPK phosphorylation and CAR localization 
following Cd2+ treatment in hUGT1 neonates. Twelve-day old neonatal hUGT1 
mice were treated with vehicle or Cd2+ (10mg/kg po.) and intestinal tissues were 
collected 30, 60, 120, and 240 minutes after exposure. Intestinal protein extracts 
were fractionated into nuclear and cytosolic components, and changes in (A) nuclear 
P38 content and phosphorylation status, (B) cytosolic ERK1/2 content and 
phosphorylation status, and (C) CAR localization were visualized by Western blot 
analysis with H3 and tubulin for nuclear and cytoplasmic loading controls. 
Quantifications and statistical analyses for A, B, and C can be found in 
supplementary figures 13, 14, and 15, respectively. 
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 The observed changes in MAPK activation are consistent with known 
regulatory mechanisms for CAR by ERK 21 and P38 17, supporting the observation 
that cadmium exposure activates intestinal CAR. The increased oxidative state 
following Cd2+ treatment, the activation of MAPK pathways, and the commensurate 
nuclear accumulation of CAR underlies the induction of intestinal UGT1A1. 
 
PEITC induction of UGT1A1 retains CAR-dependency pattern in hUGT1/Nrf2-/- 
mice. 
The observation of CAR-dependent regulation of hepatic UGT1A1 by pro-
oxidants was observed using neonatal hUGT1/Car-/- mice treated with PEITC 93. The 
tissue-specific induction patterns of hepatic and intestinal UGT1A1 and Cyp2b10 
genes were observed in the hUGT1/Nrf2-/- neonatal mice. The increased clearance of 
bilirubin in neonates treated with PEITC occurred concomitantly with increases in 
liver and intestinal expression of UGT1A1 and Cyp2b10 (Fig. 14).The inducibility of 
intestinal UGT1A1 by PEITC was reduced in hUGT1/Nrf2-/- (16.2-fold) mice 
compared to hUGT1/Nrf2+/- mice (30.3-fold) (Fig. 14). No difference was observed in 
liver UGT1A1 induction between hUGT1/Nrf2+/- and hUGT1/Nrf2-/- neonates and the 
induction of Cyp2b10 was greatest in the liver (Fig. 14). These observations are 
consistent with the previous report on CAR-dependency of hepatic UGT1A1 induction 
and CAR-independent intestinal UGT1A1 induction by PEITC 93.  
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Figure 14. Hepatic and intestinal induction of UGT1A1 and Cyp2b10 in 
hUGT1/Nrf2 neonatal mice. Ten-day old hUGT1/Nrf2 +/- and hUGT1/Nrf2 -/- 
neonates were treated with vehicle (blue circles) or PEITC (200mg/kg od. po.) (red 
squares) for two days before collecting liver and small intestine. Gene expression for 
UGT1A1 and Cyp2b10 in each tissue were examined by RT-qPCR. (Mean +/- SEM, 
Two-way ANOVA; * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001)  
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Discussion 
 It has been previously demonstrated that ITCs are capable of CAR-dependent 
induction of liver UGT1A1 93. It is well-established that NRF2 is the master regulator 
of the antioxidant response and can induce UGT1A1 66. Nuclear receptors are 
susceptible to high levels of mutual regulation 96 from shared protein interaction 
partners or through binding interactions at regulatory elements, therefore it was 
hypothesized that oxidative stress could be co-activating CAR through NRF2. The 
role of oxidative stress in the regulation of NRF2 and CAR target genes in 
hUGT1/Nrf2-/- mice was investigated. As anticipated, NRF2-deficient mice do not 
generate the antioxidant response when challenged with Cd2+. However, the 
hUGT1/Nrf2+/- mice exhibited a diminished antioxidant response in comparison to WT 
mice, suggesting haploinsufficiency.  
 By breeding Nrf2-/- mice with hUGT1 mice, pro-oxidants could be screened for 
their ability to reduce TSB levels and examine the impact of this action in an NRF2-
dependent fashion. The NRF2-KEAP1 pathway is not required for Cd2+ and ITCs to 
induce intestinal UGT1A1 in hUGT1 mice to reduce TSB levels. This supports the 
hypothesis that CAR can be activated by oxidative stress 93. In analysis of NR 
activity, we observed suppression of target genes for PXR and PPARα and slight 
induction of the AhR target gene, Cyp1a1, in WT mice (Fig. S11). The reason for the 
suppression is unclear, but the latter induction could have resulted from co-regulation 
of Cyp1a1 by NRF2 and the AhR 97. The loss of this induction in the heterozygous 
mice can be linked to haploinsufficiency of NRF2, and there was little change in the 
Nrf2-/- mice. From the examined NRs, there was evidence for CAR’s activation from 
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induction of the Cyp2b10 gene. Attempts were made to confirm protein induction of 
CYP2B10, but the expression levels were too low for detection. Subsequently, CAR’s 
activation was assayed more directly. In the absence of a readily available antibody 
for phosphorylated CAR, fractionated intestinal samples from neonates treated with 
Cd2+ were analyzed for CAR nuclear localization. After an acute cadmium exposure, 
CAR localized to the nucleus in an NRF2-independent manner, which indicates that 
co-activation of CAR by NRF2 is not responsible for the induction of intestinal 
UGT1A1 and the reduction of TSB levels.  
The increase in ERK1/2 phosphorylation is a confounding factor in the 
mechanism of CAR’s activation, given that p-ERK1/2 inhibits the activation of p-
Thr38-CAR, keeping it sequestered in the cytoplasm 26. However, in cardiac 
ventricular myocytes, it has been reported that ERK1/2 can be dephosphorylated by 
PP2A activity that is dependent upon the activation of P38 98. Furthermore, the 
phosphorylation status of ERK1/2 and P38 can be increased by H2O2 and As3+ 
respectively, both of which are linked to oxidative stress. The observation of a 
consistent nuclear accumulation of CAR during the decay of the p-ERK signal at the 
2- and 4-hour time points suggests the reduction in ERK1/2 activity is sufficient to 
permit CAR activation, which occurs concurrently with the nuclear accumulation of 
P38/p-P38. In order for CAR to translocate to the nucleus, it must first be 
dephosphorylated by PP2A 25 in order to interact with P38 to increase CAR’s 
transactivation activity 17. Activated P38 phosphorylates CAR at the conserved Thr38 
residue to export CAR from the nucleus. These changes in the phosphorylation 
status of P38 and ERK1/2 were also observed in whole-cell lysate from a hUGT1 
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adult time course (data not shown), supporting our hypothesis of the oxidative stress-
MAPK-CAR axis.  
It has been reported that intestinal differentiation and crypt formation involves 
ROS and the activation of P38 99,100. Intestinal maturation is essential to both nutrient 
uptake and metabolic waste/toxicant removal. From studies in hUGT1 mice, early 
intestinal expression of UGT1A1 is important to metabolize bilirubin while hepatic 
UGT1A1 expression is developmentally delayed 58. Maturation of intestinal epithelial 
cells can be estimated by the decreases in genes related to cell stemness and the 
increase of functional genes related to the differentiated cell types. For example, the 
brush border glucosidase known as sucrose isomaltase, SIS, is only expressed in 
maturing and mature duodenum and jejunum enterocytes 101. Alternatively, the Lrp2 
gene encodes for a protein known as megalin, which mediates nutrient uptake by 
endocytosis, and it’s expression in the jejunum and ileum is down regulated as those 
tissues develop102. These and other genes, like Glb1 and Krt20 are markers for 
intestinal maturation when down- and up-regulated, respectively 67. Intestinal 
maturation markers were examined and it was determined that low doses of Cd2+ 
may induce intestinal maturation as inferred by inhibition of the Glb1 and Lrp2 genes 
and the induction of the Sis and Krt20 genes (Fig. S12). Recently, it was reported 
that the nuclear receptor corepressor 1 (NCoR1), which regulates CAR activity at the 
PBREM 23, is also capable of regulating intestinal maturation 67. Intestinal epithelial 
cell specific knockout of NCoR1 leads to changes in maturation markers and 
induction of UGT1A1 similar to what was observed herein 67. Thus, it may be 
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possible that Cd2+ cadmium inhibits NCoR1, which increases maturation and de-
represses CAR’s transcriptional activity.  
The most obvious implication of the oxidative stress-MAPK-CAR signaling axis 
is that those individuals with higher intestinal and hepatic CAR activity from 
environmental pro-oxidants, such as heavy metals from smoking or contaminated 
drinking water and soil, or from indirect antioxidants found in certain diets and 
commercial supplements will also have increased metabolism of UGT1A1 and 
CYP2B6 substrates. For example, bupropion, an anti-depressant and smoking 
cessation aid, is hydroxylated by CYP2B6 in the liver to hydroxybupropion, which is 
both pharmacologically active and the major metabolite 103. Alternatively, the 
chemotherapeutic agent cyclophosphamide is bio-activated in the liver by CYP2B6, 
which would increase both toxicity and therapeutic effectiveness 104. Regarding 
UTG1A1, irinotecan is a chemotherapeutic agent for colorectal cancer and the 
activated metabolite SN-38 is detoxified by UGT1A1, increased intestinal and colonic 
activity of UGT1A1 would reduce the treatment side effects 92. Additionally, raloxifene 
is used to treat osteoporosis and the major metabolites are glucuronides where 
increases in UGT1A1 would decrease availability and treatment effectiveness 105. It is 
possible that future studies making use of RNA-seq, metabolomics, and exposure 
data may reveal a correlation between pro-oxidant, toxicant exposure, and an 
individual variability in xenobiotic metabolism stemming from CAR activity.  
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CHAPTER 4: MECHANISTIC CONSIDERATIONS OF CAR ACTIVATION BY 
OXIDATIVE STRESS 
Section 4.1 CAR and NRF2 Crosstalk 
Arsenic and cadmium are environmentally relevant toxicants that are ranked 
number 1 and 7, respectively, on the agency for toxic substances and disease 
registry’s (ATSDR) substance priority list. The dietary prooxidant PEITC and its 
antitumoral properties106  has been the subject of many investigations, including that 
of an interventional clinical trial (NCT03700983). These toxicants can exert their 
effects on drug metabolism through the depletion of cellular glutathione to induce 
oxidative stress and activate the NRF2-KEAP1 pathway. The activation of CAR by 
PEITC and heavy metals, as examples of prooxidant toxicants in general, was initially 
thought to be a form of crosstalk between the master regulator of the antioxidant 
response, NRF2, and CAR. An alternative pathway for the regulation of drug 
metabolism by oxidative stress could be inferred by the observation that P38, could 
increase CAR transcriptional activity and initiation cytoplasmic localization16. This is 
of note because it was previously understood that ERK1/2, another MAPK, had a 
repressive effect on CAR. Furthermore, NF-kB activates following substantial 
amounts of oxidative stress, which leads to the repression of many nuclear 
receptors107,  making CAR a potential target. At first glance the action of MAPK and 
NF-kB would suggest that CAR is inhibited by oxidative stress. However, CAR is not 
directly repressed by NF-kB like other nuclear receptors, and there are multiple 
reports that indicate a crosstalk between CAR and NRF2, suggesting that NRF2 
activity would be the source of CAR activation. These investigations included the 
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activation of CAR by phorone81, oltripaz108, allyl sulfide109, trans-stilbene oxide110, and 
the induction of NRF2 targets by CAR activators111. The latter of these is of interest in 
the context of nuclear receptor crosstalk because CAR activity precedes the 
activation of NRF2 but does not appear to be dependent upon CYP450-induced 
oxidative stress, which is a reported mechanism for ROS production112,113. All of the 
above chemicals can deplete cellular glutathione, but only trans-stilbene oxide has 
been examined for direct CAR binding and was determined to be a ligand based 
upon concentration dependent recovery of CAR target gene induction from 
androstenol inverse agonism110. It may prove useful to establish if other xenobiotics 
activate CAR independently of NRF2 in vivo by using the hUGT1/NRF2 mouse 
model. 
In contrast to the crosstalk others have observed, NRF2-independent 
induction of UGT1A1 by prooxidants suggests another redox sensitive pathway is 
activating CAR. While there are no independent reports of Cd2+ activating CAR, there 
are reports of PEITC inducing cyp2b15114 and sulforaphane increasing bilirubin 
glucuronidation115 and CYP2B activity116. It has been reported in vitro that cancer 
cells experience reduced EGFR activation when treated with PEITC117. This raises 
the possibility that indirect activation, not oxidative stress, could be the cause of CAR 
activation; however, these effects were modest and occurred in prostate cancer cells. 
Additionally, we were unable to activate CAR with PEITC in vitro using mouse 
primary hepatocytes, which are responsive to indirect mechanisms of activation. A 
direct ligand binding assay showed no activation by PEITC (Fig. S16). It appears 
PEITC is not capable of activating mouse CAR from a phenobarbital-like indirect 
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mechanism. One reason that PEITC may not be able to induce UGT1A1 in primary 
hepatocyte culture but is capable in vivo could be either by gut microflora or first pass 
metabolism through the intestine. However, when neonatal mice were 
intraperitoneally treated with 50mg/kg PEITC, treated mice experienced reductions in 
TSB values in an NRF2-independent manner (Fig. S17). This I.P. administration 
bypasses potential bioactivation from microbial or intestinal metabolism. Additionally, 
supplementing mice with N-acetylcysteine in drinking water prevented hepatic 
induction of oxidative stress genes and CAR target genes Cyp2b10 and UGT1A1, 
which suggests oxidative stress rather than EGFR inhibition.  
Section 4.2 CAR and MAPKs 
The activation of the MAPK’s is of interest because they control a variety of 
cellular responses to different types of stress. Following its activation by oxidative 
stress, P38 both activates and inhibits CAR. Negishi and colleagues proposed that p-
P38 increases the activity of transcription factors that increase CAR activity. These 
factors include PGC1a118, C/EBPa119, HFN4a120, and SRC1121. All but the SRC1 
study have directly implicated P38 phosphorylation of the transcription factor as an 
activating step. This would either require multiple p-P38 proteins as CAR is also 
phosphorylated by p-P38 and/or an exchange of the phosphate group from one of 
the transcription cofactors to CAR, thereby decreasing the activity of the cofactor and 
excluding CAR from the nucleus. In this way, both the activating function of P38 and 
the phosphorylation of Thr38 could be explained. However, under this hypothesis, 
the activation of CAR by prooxidants does not explain the initial increase in nuclear 
CAR accumulation. The increase in CAR activity by the examined toxicants could be 
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due to derepression instead of or in addition to the proposed mechanism above as 
they are not mutually exclusive.  
In this derepression hypothesis, the combination of three separate 
phosphorylation changes prompted by p-P38 could explain both the activation of 
CAR by oxidative stress, as we have observed and repression following transcription 
as it has been described by Negishi and colleagues. The activation of P38 leads to 
increases in PP2A activity, which has two separate activating steps; the 
dephosphorylation of ERK1/2 and the dephosphorylation of Thr38-CAR. The basis 
for oxidative stress activation of PP2A by P38 has been examined in vitro using 
several cell types. The first study details the increase in P38 phosphorylation 
following sodium arsenite exposure in cardiac ventricular myocytes, which 
subsequently dephosphorylates H2O2-activated ERK1/2 in an PP2A-dependent 
manner98. The second study utilized endothelial somatic hybrid cells to demonstrate 
that P38 mediates a PP2A-dependent inhibition of the MEK-ERK pathway122. The 
third study was performed in human skin fibroblasts and demonstrated that arsenite 
activated P38, leading to PP2A dephosphorylation of the phorbal ester-activated 
MEK-ERK pathway123. 
 ERK1/2 acts as a major repressor of CAR nuclear localization as it has been 
demonstrated that a reduction in ERK1/2 phosphorylation by MEK inhibitor U0126 is 
sufficient to induce CAR translocation to the nucleus21. First, the dephosphorylation 
of ERK1/2 allows the CAR homodimer complex to dissociate and reveal the 
RACK1:PP2A binding interface19. Second, the RACK1:PP2A complex 
dephosphorylates Thr38, which is the essential regulatory step for cytoplasmic 
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localization18. The last phosphorylation event is performed by p-P38 acting on Thr38-
CAR to initiate cytoplasmic localization17. Between the second and third steps, 
changes in phosphorylation drive p-P38 to activate cofactors and increase CAR 
transcriptional activity. Alternatively, p-P38 may lead to increased activity of PP2A 
and decreased ERK1/2 phosphorylation. 
The phosphorylation of ERK1/2 is a rapid event that peaks within 30 minutes 
and then decays, potentially derepressing CAR. It is unclear if the activation of 
ERK1/2 causes additional repression because CAR is already principally localized in 
the cytoplasm under basal conditions. Decreases in CAR phosphorylation and 
dissociation of the CAR homodimer complex can be expected following the drop in 
ERK1/2 phosphorylation; however, only one phospho-specific antibody for CAR has 
ever been created and could not be obtained for use. The nuclear accumulation of 
intestinal CAR following cadmium exposure occurs concomitantly with the drop in 
ERK1/2 phosphorylation, which suggests a derepression mechanism. Additional time 
course experiments with other indirect NRF2/CAR activators such as oltipraz or 
arsenic may show similar patterns of localization and phosphorylation.  
Section 4.3 CAR and HIF1a 
Other redox sensitive proteins were investigated as potential sources of CAR 
activation, such as HIF1a and FOXO1. There have been reports that ROS can 
stabilize HIF1a124. A report of crosstalk between HIF1a and CAR implicated HIF1a as 
a potential coactivator of CAR125. In HepG2 cells and the livers of mice, CoCl2, a 
stabilizer of HIF1a, led to the increase of CAR transcriptional activity and increased 
association of both CAR and HIF1a at the PBREM125. However, these effects were 
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not investigated in small intestine. To examine the effect of HIF1a on CAR activation 
in the intestines, neonatal hUGT1 mice were treated with CoCl2 or water on day 10 
and CdCl2 on day 11. TSB values were collected on days 11 and 12 to determine if 
CoCl2 treatment was sufficient to induce UGT1A1. As shown in Figure S18, CoCl2 
does not induce UGT1A1 by itself but pretreatment with CoCl2 followed by CdCl2 had 
a greater effect in lowering TSB values than water pretreatment. The effect of HIF1a 
in this experiment is likely intestinal as CdCl2 does not accumulate in the liver to a 
significant degree using this protocol. A caveat is that this experiment was performed 
in hUGT1 mice, and so the contribution of NRF2 to the lowering of TSB values and 
the possible interaction of HIF1a and NRF2 prevents confirming the crosstalk 
between CAR and HIF1a. Performing this experiment in Nrf2-null and Car-null mice 
would be a better approach; however, is it known that CdCl2 destabilizes HIF1a and 
so two treatments of CdCl2 may reduce HIF1a to levels where ROS activation has a 
negligible effect. This calls into question to relevance of HIF1a to ROS activation of 
CAR, as a single dose of 10mg/kg CdCl2 does not typically lower TSB values to 0-1, 
but these values can be obtained with two doses, by which point HIF1a levels might 
be too low to have an effect. The effect observed by increasing HIF1a content is 
likely due to another mechanism by which CAR activity is increased rather than what 
is observed with PEITC and Cd2+.  
The validity of overexpressing components to determine their role in CAR 
activation is a recurring issue for in vitro mechanism studies as they diverge from the 
complexity associated with a full biological system but are necessary to obtain 
positive data. For example, in immortalized cell lines CAR is typically overexpressed 
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by transient or stable transfection, and the transformed CAR is constitutively active in 
hepatomas, which are useful cell lines given the in vivo expression of CAR is highest 
in the liver; however, primary hepatocyte cultures do not exhibit constitutive nuclear 
accumulation of CAR. There are phenotypic consequences to studying CAR in 
different models as phenobarbital is incapable of inducing CAR target gene 
expression in hepatomas but does induce expression in primary hepatocytes. The 
reason for this is unknown but may have something to do with low levels of P38 
activity in HepG2 cells, which may prevent the initiation of cytoplasmic localization 
following transcription activation.  
Section 4.4 CAR and FOXO1 
The transcription factor FOXO1 increases CAR transcriptional activity at its 
expense due to sequestration from its target binding elements upon interacting with 
CAR126. This is the basis for some of CAR’s ability to regulate energy homeostasis 
through mechanisms like inhibiting expression of the rate limiting enzyme for 
gluconeogenesis, PEPCK1 (Pck1). The redox regulation of FOXO1 is mediated 
through its phosphorylation by AKT that signals for nuclear exclusion and through 
increasing mRNA stability by RNA-binding proteins containing reactive cysteine 
residues127. Following PEITC exposure in hUGT1 neonates, hepatic Pck1 mRNA 
expression was inconsistently down regulated between independent experiments 
while Foxo1 mRNA was unaffected. Similar inconsistencies were observed in 
neonatal intestinal samples of hUGT1/Nrf2 mice treated with CdCl2. In hUGT1 
neonatal mice, FOXO1 protein could not be detected, therefore adults were utilized. 
A time course was performed in adults treated with PEITC and their livers were 
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fractionated for nuclear content. Following PEITC administration FOXO1 is excluded 
from the nucleus (Fig. S19), presumably due to increased AKT activity, and thus is 
not responsible for the increase in CAR activity. 
 Much of the work presented herein has been in examination of redox sensitive 
factors that could be responsible for increases of CAR target gene expression 
following prooxidant exposure. While other mechanisms may exist that act in an in 
vivo context to coactivate CAR, it seems likely that MAPK regulation is responsible 
for the increases of CAR nuclear accumulation and activity. 
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CHAPTER 5: CLOSING COMMENTS 
 The activation of CAR by the prooxidants arsenic, cadmium, and PEITC 
represents a novel mechanism for the regulation of drug metabolism in an in vivo 
context with phenotypic consequences. Initial observations of ITCs inducing phase II 
drug metabolizing enzymes led to the study of PEITC in the humanized UGT1 mouse 
model. The use of neonatal hyperbilirubinemia enables faster determinations of 
nuclear receptor dependency of regulation of drug metabolism by xenobiotics. In the 
course of these examinations, it was determined that CAR was responsible for the 
induction of UGT1A1 and CYP2B10 in neonatal and adult mice. The CAR 
dependency, however, was a tissue-specific phenomenon. While hepatic control of 
UGT1A1 was CAR-dependent, intestinal induction of UGT1A1 was, in part, 
dependent upon NRF2. This was concluded through gene expression analysis and 
the generation of a new humanized UGT1 mouse model in an Nrf2-null background. 
The generation of the hUGT1/Nrf2 mouse model and the potential for a Car/Nrf2 
double knockout mouse model comes at an opportune time given the recent reports 
detailing CAR-NRF2 crosstalk. However, such crosstalk was not responsible for the 
activity of CAR following exposure to prooxidants, which begs the question what 
redox sensitive mechanism is responsible for regulating CAR.  
These preliminary investigations suggest that HIF1a and FOXO1 are not likely 
to be responsible for CAR’s increased nuclear accumulation, which is an underlying 
feature of CAR activity. It is likely that the increase in CAR activity by oxidative stress 
is a multifactorial response given the numerous redox sensitive pathways that either 
directly or indirectly affect CAR. Some clues to the activation of CAR may come from 
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tissue specific dependency of UGT1A1 induction by PEITC; however, PEITC alone is 
insufficient to implicate oxidative stress as the essential regulatory component given 
that a variety of mechanisms of action have been reported for its antitumor 
properties. By expanding the investigation of prooxidants to the environmentally 
relevant toxicants arsenic and cadmium, the role of oxidative stress is reinforced and 
the implications of this work are potentially extended to the study of environmental 
factors that may explain individual variability in pharmaceutical treatments. It is worth 
noting that all of the experiments presented herein were acute exposures, and 
studies into the regulation of CAR by constant oxidative stress may yield different 
results. 
 An additional avenue of research is the effect of oxidative toxicants on the 
development of the intestines. Are the changes in maturation markers following 
PEITC and cadmium exposure reflected in proliferative cell populations? If so, is 
there a link to the increase in UGT1A1 expression as it relates to CAR and NRF2 
dependency? Some answers may reside in other regulatory factors such as NCoR1, 
but other poorly understood avenues remain, such as the role of AMPK signaling or 
microRNA regulation. What is clear in any event is that the regulation of CAR 
localization is dependent upon proper recognition and activity of PP2A. The 
mechanism by which nuclear accumulation of CAR by Thr38 dephosphorylation is 
unknown and may present additional explanations of CAR activity following 
prooxidant exposure. Herein, a definitive link between the activation of CAR by 
diverse toxicants that induce oxidative stress has been shown. This activation of CAR 
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regulates drug metabolism with phenotypic consequences and is not a result of 
crosstalk with the master regulator of the antioxidant response, NRF2. 
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APPENDIX (Supplemental Materials) 
Supplemental Figures 
 
 
Supplemental Figure 1. Analysis of Nrf2 target genes. Using RNA isolated in 
Figure 1 (neonatal hUGT1 mice), gene expression patterns for Nqo1, Gsta1 and 
Gsta2 were quantitated by RT-qPCR expressed as Fold induction. Values are the 
means of ± SD (n=3). Statistically significant differences between vehicle (Veh) and 
PEITC are indicated by asterisks (Student t test: *, P<0.05).  
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Supplemental Figure 2. Oxidative stress following PEITC treatment. A. Neonatal 
hUGT1 mice were given an oral dose of PEITC (200 mg/kg) and GSSG levels 
measured in liver and small intestine (SI) after 24 hours. B. The same experiment 
was conducted on adult (6 week old) hUGT1 mice. Values are the means of ± SD 
(n=3). Statistically significant differences between vehicle (Veh) and PEITC are 
indicated by asterisks (Student t test: *, P<0.05).  
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Supplemental Figure 3. Impact of PEITC on Nrf2 target genes in adult mice. 
RNA prepared from PEITC treated hUGT1/Car+/- and hUGT1/Car-/- mice from liver 
and small intestine (Figure 4) was used to quantitate Nqo1, Gsta1 and Gsta2 gene 
expression by real time PCR. Values are the means of ± SD (n>3). Statistically 
significant differences between vehicle (Veh) and PEITC are indicated by asterisks 
(Student t test: *, P<0.05; **, P<0.01).  
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Supplemental Figure 4. Full length Western blot used for Figure 3.  
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Supplemental Figure 5. Full length Western blots used for Figure 4.  
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Supplemental Figure 6. Full length Western blots used for Figure 5.  
 
 
Supplemental Figure 7. Full length Western blot used in Figure 6. 
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Supplemental Figure 8. Full length Western blots used for Figure 7. 
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Supplemental Figure 9. Full length Western blots used for Figure 8. 
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Supplemental Figure 10. Changes in TSB levels of hUGT1/Nrf2 neonates 
treated with As3+, Cd2+, or PEITC. Ten-day old hUGT1/Nrf2 +/- and hUGT1/Nrf2 -/- 
neonates were treated with vehicle (water or corn oil) or As3+ (10 mg/kg od. po.) or 
Cd2+ or PEITC (200 mg/kg od. po.) for two days before collecting blood for TSB 
measurements (mg/dL). (Mean +/- SEM, Two-way ANOVA; *** P<0.001, **** 
P<0.0001) 
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Supplemental Figure 11. Changes of intestinal Cyp gene expression in 
hUGT1/Nrf2 neonates exposed to Cd2+. Ten-day old hUGT1/Nrf2+/+, hUGT1/Nrf2+/-, 
and hUGT1/Nrf2-/- neonates were treated with vehicle (blue circles) or Cd2+ (10 mg/kg 
od. po.) (red squares) for two days before collecting intestinal tissues. Changes in the 
expression of Cyp1a1, Cyp2b10, Cyp3a11, and Cyp4a10 were examined by RT-
qPCR. (Mean +/- SEM, Two-way ANOVA; * P<0.05, ** P<0.01, **** P<0.0001) 
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Supplemental Figure 12. Changes of intestinal maturation markers in 
hUGT1/Nrf2 neonates treated with Cd2+. Ten-day old hUGT1/Nrf2+/+, hUGT1/Nrf2+/-
, and hUGT1/Nrf2-/- neonates were treated with vehicle (blue circles) or Cd2+ (10 
mg/kg od. po.) (red squares) for two days before collecting intestinal tissues. 
Exposure to Cd2+ altered intestinal gene expression of Glb1, Lrp2, Krt20, and Sis as 
examined by RT-qPCR. (Mean +/- SEM, Two-way ANOVA; * P<0.05, ** P<0.01, *** 
P<0.001, **** P<0.0001) 
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Supplemental Figure 13. Ratio of intestinal, nuclear P38 at various time points 
from Cd2+ exposed hUGT1 neonates relative to vehicle treated littermates. Day-
12 neonatal hUGT1 mice treated with vehicle or cadmium (10mg/kg po.) and 
sacrificed at 30, 60, 120, and 240 minutes following exposure. Intestinal samples 
were collected, and nuclear and cytoplasmic protein fractions were isolated. Western 
blot analysis was performed on the nuclear fractions for P38, P-P38, and H3. Bands 
were quantified and ratios of relative nuclear P38 content (P38/H3) from cadmium 
exposed hUGT1 neonates were set relative to vehicle treated littermates. (Mean +/- 
SEM, One-way ANOVA) 
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Supplemental Figure 14. Ratios of phosphorylated to unphosphorylated 
ERK1/2 in Cd2+ exposed hUGT1 neonates set relative to vehicle treated 
littermates at various time points. Day-12 neonatal hUGT1 mice treated with 
vehicle or cadmium (10mg/kg po.) and sacrificed at 30, 60, 120, and 240 minutes 
following exposure. Intestinal samples were collected and nuclear and cytoplasmic 
protein fractions were isolated. Western blot analysis was performed on the cytosolic 
fractions for ERK1/2, P-ERK1/2, and Tubulin. Bands were quantified and a 
comparison of the ratios of P-ERK1/2 / ERK1/2 for cadmium exposed mice relative to 
vehicle treated littermates was created. (Mean +/- SEM, One-way ANOVA, * P<0.05, 
** P<0.01) 
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Supplemental Figure 15. Quantification of nuclear CAR localization at various 
time points following Cd2+ exposure in hUGT1 neonates. Day-12 neonatal 
hUGT1 mice treated with vehicle or cadmium (10mg/kg po.) and sacrificed at 30, 60, 
120, and 240 minutes following exposure. Intestinal samples were collected, and 
nuclear and cytoplasmic protein fractions were isolated. Western blot analysis was 
performed on the nuclear fractions for CAR and H3. Bands were quantified and ratios 
of nuclear CAR relative to total protein (H3) were established. (Mean +/- SEM, One-
way ANOVA, * P<0.05) 
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Supplemental Figure 16. PEITC Transactivation of GAL4 DBD-hCAR LBD. CV-1 
cells were transfected with plasmids encoding for: (1) the GAL4 DNA binding domain 
fused to the hCAR ligand binding domain, (2) the firefly luciferase gene driven by the 
GAL4 promotor, and (3) a control Renilla luciferase. The assay was performed using 
the Dual-Glo® Luciferase Assay System by Promega. Cells were treated with vehicle 
DMSO, direct ligand CITCO, nontoxic concentrations of PEITC, and indirect activator 
phenobarbital (PB). Firefly luciferase activity was measured in accordance with the 
manufacturer’s protocol following a 24hr incubation period with the respective 
compounds. Values are representative of two independent experiments with five 
biological replicates per group.  
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Supplemental Figure 17. Total serum bilirubin levels of hUGT1/Nrf2 neonatal 
mice following IP administration of PEITC. Day-10 neonatal hUGT1/Nrf2+/- and 
hUGT1/Nrf2-/- mice were treated with vehicle (blue circles) or 50mg/kg PEITC (red 
squares) by I.P. for two days before collecting blood for TSB (mg/dL) measurements. 
(Mean +/- SEM, Two-way ANOVA; **** P<0.0001) 
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Supplemental Figure 18. Total serum bilirubin levels of hUGT1 neonatal mice 
following oral pretreatment with CoCl2 and challenge with CdCl2. Day-10 
neonatal hUGT1 mice were treated with vehicle (blue circles) or 70mg/kg CoCl2 (red 
squares) by oral gavage. On day 11, blood was collected and all mice were treated 
orally with 10mg/kg CdCl2. Blood was collected on day 12 and TSB values were 
measured (mg/dL). (Mean +/- SEM, student’s t-test; * P<0.05) 
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Supplemental Figure 19. Hepatic FOXO1 localization following oral PEITC 
treatment of hUGT1 adults. Adult mice (12 weeks old) were treated orally with 
PEITC 200mg/kg and livers were collected at various time points. Livers were 
fractionated for nuclear and cytoplasmic content and a Western blot analysis was 
performed for FOXO1.   
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